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From birth, man carries the weight of gravity on 
his shoulders. He is bolted to earth. But man has 
only to sink beneath the surface and he is free.  
J. Y. Cousteau 
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INTRODUCTION 
 
A BRIEF INTRODUCTION:  
VASCULOGENESIS AND ANGIOGENESIS 
 
PHYSIOLOGICAL VASCULOGENESIS AND ANGIOGENESIS 
The mechanism of blood vessel formation, from the embryo to adult life, has been the subject of a 
large number of studies which aimed at understanding the fine molecular pathways underlying such 
process. In the very early stages of embryonic development, nutrients are received by diffusion, and 
only in a second time a complex network of capillaries and blood vessels develop with the aim of 
carrying oxygen and nutrients to organs and tissues and removing their catabolic waste (Noden, 
1989). 
The creation of running capillaries, veins and arteries takes place through two main phases (Figure 
1). The first is called vasculogenesis and starts in the yolk sac where mesenchymal cells in the 
periphery, and hematopoietic stem cells (HSC) in the center, give rise to the so called “blood 
islands”, the well documented first site of hematopoiesis and vascular development during 
embryogenesis (Ferkowicz and Yoder, 2005). Angioblasts, the precursors of endothelial cells 
(ECs), and hematopoietic cells emerge near each other in blood islands, and have common surface 
antigen markers, hence the concept that a common precursor to hematopoietic and endothelial 
lineage can exists (hemangioblast). The concept of hemangioblast was proposed nearly a century 
ago based on the close proximity of cells in the yolk sac that give rise to both blood cells and blood 
vessels. This hypothesis is supported by studies using in vitro mouse and human embryonic stem 
cells cultures, and in vivo animal model systems including zebrafish, chick, and mice. During 
vasculogenesis, angioblasts migrate towards different places where they can differentiate and give 
rise to endothelial cords and to the primitive vascular network (Carmeliet, 2000). Angioblast 
recruitment and differentiation is driven by a myriad of cytokines and growth factors, such as 
vascular endothelial growth factor (VEGF), granulocyte monocyte-colony stimulating factor (GM-
CSF) and fibroblast growth factor (FGF) (Ferrara et al., 1996; Swift and Weinstein, 2009). 
This primitive vasculature network is remodeled and extended by angiogenesis, the second step of 
vessel formation, as profusely described by Conway et al., 2001. Angiogenesis can in turn be 
divided in different steps listed below: 
• Vasodilation of existing vessels, mainly in response to nitric oxide (NO) and VEGF; 
• Increase in permeability after a modification in the distribution of intracellular adhesion 
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molecules, such as platelet endothelial cell adhesion molecule (PECAM-1) and vascular 
endothelial (VE)-cadherine; 
• Extravasation of plasma proteins with the creation of a scaffold for ECs, and degradation of 
surrounding matrix that involves many different matrix metalloproteinases (MMPs) (Nelson 
et al., 2000); 
• Migration of activated and proliferating ECs controlled by a finely tuned balance of 
activators and inhibitors factors, such as VEGF, angiopoietins, FGF, and their receptors; 
• EC differentiation and subsequent interaction with extracellular matrix and periendothelial 
cells, i.e. pericytes or smooth cells in small and large vessels, respectively; this latter process 
has been called vascular myogenesis (Conway et al., 2001); 
• EC assembly into solid cords and subsequent formation of the lumen through interaction of 
ECs with both extracellular matrix and existing vessels. Lumen size is tightly regulated by 
several factors, like VEGF, Angiotensin 1 and multiple integrins (Suri et al., 1998); 
• Finally, during arteriogenesis, smooth muscle cells create a thick stabilizing coat around 
vessels that become viscoelastic and with vasomotor characteristics.  
 
 
Figure1. Development of the vascular system (PC: pericytes, SMC: smooth muscle cells) 
(Carmeliet, 2005). 
 
 
Therefore, the vasculogenic process takes place during embryogenesis, followed by angiogenesis 
which continues also after birth when it contributes to organs growth. In adult life, most of blood 
vessels remain in a quiescent state, and ECs are arrested in the G0 phase of cell cycle. However, 
vasculogenesis can be resumed in particular physiological conditions, such as ovary cycle, 
pregnancy, or wound repair, by bone marrow- or arterial wall-derived angioblasts or endothelial 
progenitor cells (EPCs).  
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ENDOTHELIAL PROGENITOR CELLS (EPCs) 
The dogma that vasculogenesis takes place only during embryonic development has been 
completely revolutionized in 1997 by Asahara et al. who identified for the first time endothelial 
progenitor cells (EPCs) in peripheral blood (PB) of adult subjects (Asahara et al., 1997). EPCs have 
been defined as cells with self-renewal capacity, able to differentiate in vitro in mature ECs and 
generate patent vessels in vivo through a process termed postnatal vasculogenesis (Khakoo and 
Finkel, 2005). EPCs can be isolated from mononucleated cells (MNCs) of bone marrow (BM), 
peripheral blood (PB), umbilical cord blood (UCB) but also from the wall of large arteries (Yoder, 
2012). The seminal paper by Asahara et al. (1997) clearly stated the thesis that a subset of cells 
circulating in PB function as progenitors of the endothelial lineage, both in vitro and in vivo. 
Following the first Asahara’s work, an intensive investigation allowed to understand that the cells 
identified by Asahara were not real EPCs because they rather belong to the hematopoietic lineage, 
as better described below. Nevertheless, the concept that endothelial precursors circulate in PB of 
adult individuals was correct, but it took much longer to isolate the cells with the characteristics of 
true endothelial progenitors.  
 
 IDENTIFICATION OF EPCs 
As well described by Prater et al. (2007), three methods have been explored to identify true EPCs in 
vitro (Figure 2) (Prater et al., 2007).  
Asahara in 1997 at first, and subsequently Hill et al. in 2003, isolated the so called colony-forming 
unit-endothelial cells (CFU-ECs) or CFU-Hill (Hill et al., 2003). They plated PB-MNC on 
fibronectin-coated dishes and after 48 hours of culture non-adherent cells were recovered and 
replated on fibronectin-coated dishes. Colonies of round cells in the centre and spindle-shaped cells 
in the periphery appeared after 5-9 days of culture. Even though CFU-ECs expressed on their 
surface antigens specific for endothelial lineage, such as CD31, CD105, CD144, VWF, KDR and 
UEA-1, they also presented the hematopoietic-specific cell surface antigen CD45 and the antigens 
specific for monocyte and macrophages lineages, CD14 and CD115 (Rehman et al., 2003; Kalka et 
al., 2000). Furthermore, they did not show the specific progenitor feature of displaying high 
proliferative potential, but they stopped growing after 2 or 3 culture passages. Therefore, it was 
concluded that CFU-ECs were not representative of EPCs but were actually derived from 
hematopoietic cells (Yoder et al., 2007). 
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Figure2. Common methods of EPCs culture (Prater et al., 2007). 
 
Another method, introduced for the first time by Asahara and Dimmeler employed PB-MNCs 
plated on fibronectin-coated plates for 4 days in a supplemented endothelial growth medium; after 
this period, non adherent cells were discarded and a population of single spindle-shaped cells 
remained adherent to the culture dish. They called these cells “circulating angiogenic cells” (CACs) 
for their characteristic of promoting neovascularization in animal models of hind limb ischemia or 
myocardial infarction. CACs expressed endothelial-specific surface antigens CD31, CD144, VWF, 
KDR (Dimmeler et al., 2001), but were not able to form colonies, did not exhibit self-renewal 
properties, and had an intermediate phenotype between hematopoietic and endothelial lineage. An 
extensive immunophenotypical characterization showed that CACs were hematopoietic by clonal 
lineage tracking, exactly as it occurred for CFU-Hill (Yoder et al., 2007). Finally, the third method, 
described by Hebbel and Ingram identified the so called “endothelial colony forming cells” 
(ECFCs). After plating PB-MNCs or UCB-MNCs in collagen treated plates with endothelial-
specific medium, non-adherent cells were discarded by gentle washes after 48 hours of culture and 
a medium change performed every 48 hours until the first colonies started do appear. It took about 
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10-21 days if the MNCs source was PB, 7-9 days if MNCs derived from UCB; colonies displayed a 
cobblestone shape, typical of ECs. ECFCs were also phenotypically indistinguishable from mature 
ECs, possessed vessel-forming ability in vivo and were able to form capillary-like structure in 
matrigel in vitro (Figure 3). 
Figure 3. EPCs colony and capillary-like structure in matrigel assay. 
 
ECFCs expressed all the endothelial-specific cell surface antigens, CD105, CD31, CD144, VWF, 
VEGFR-2, but not the hematopoietic antigens CD14 and CD45, confirming that they did not derive 
from the hematopoietic lineage. To date, many steps forward have been accomplished on the 
knowledge on ECFCs and it is clear that ECFCs are rare cells in PB of healthy adult subjects, their 
concentration being about 0.05-0.2 cell/ml (Prater et al., 2007; Yoder et al., 2007); ECFCs are able 
to participate to vessel formation in murine models of immunodeficient mouse when they have been 
injected after suspension in a collagen scaffold (Schechner et al., 2000; Yoder et al., 2007). It can 
been concluded that because ECFCs have a clonal proliferative capacity, the ability to expand for 
several passages ex vivo, to differentiate in mature ECs, and to form vessel in vivo, they display all 
the characteristics of progenitor cells and have been considered the best EPCs surrogate in vitro 
(Yoder, 2012; Basile and Yoder, 2014).  
 
PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION OF EPCs 
A definitive immuno-phenotypical characterization of EPCs is yet to be described. A big debate, 
conducted over the last 15 years, concluded that immuno-phenotypical analysis cannot truly 
identify EPCs in blood circulation. A combination of phenotypical, cultural and functional analyses 
are necessary to fully characterize these cells. At first, CD34 has been identified as a potential 
marker of circulating angioblasts, because it is known to be expressed on endothelial cells; however 
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it is also widely used to identify human hematopoietic stem and progenitor cells. For this reason, 
CD34 cannot be used as a specific EPC marker. Also KDR (or VEGFR-2), one of VEGF receptors, 
is expressed on blood, endothelial and cardiac cells, therefore it is not a big discriminating factor 
among CD34+ cells. CD133 has also been considered a potential EPC marker. Peichev et al. 
hypothesized that cells positive for CD34, KDR and CD133 were the best EPC representatives and 
these three markers have been used to identify circulating EPCs in hundreds of papers since 2000 
(Peichev et al., 2000). Case at al., however, reported that CD34+, KDR+ and CD133+ cells are 
highly enriched in hematopoietic progenitor activity and are not able to give rise to any endothelial 
colony in vitro (Case et al., 2007; Yoder et al., 2007). The debate about EPC identification went on 
and, in 2012, Mund et al. tried to clarify this confused scenario by carrying out a complex 
polychromatic flow cytometry analysis of EPCs based on an appropriate panel of optimizing 
antibodies (Mund et al., 2012). As shown in Figure 4, EPCs have been characterized as CD45 
negative cells, positive for CD34, CD31 (an endothelial-specific marker), CD146 (an adhesion 
molecule expressed by mature ECs) and CD105, or endoglin, a part of TGF beta receptor complex. 
Figure 4. Circulating EPCs identification by polychromatic flow cytometry (Mund et al., 
2012). 
 
However, besides phenotypical identification, a colony forming assay has to be used to identify 
putative EPCs. The method has already been described and is the one used by Hebbel and Ingram 
that obtained colonies with typical endothelial markers, similar to vascular endothelial cells, 
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forming blood vessels in vivo and differentiating in mature ECs (Ingram et al., 2004). ECFCs have a 
high proliferative and robust replating potential and high telomerase activity, appearing as being 
consistent with the original criteria for EPCs identification (Basile and Yoder, 2014). Moreover, 
ECFCs are able to create capillary-like structure when plated on Matrigel, a commercial mixture 
protein which mimics the basal membrane of extracellular matrix.  
 
EPC MOBILIZATION 
It has been demonstrated that EPCs resides in specific sites of BM, called niches, where cells can 
stay undifferentiated and quiescent or proceed toward a differentiated state. EPCs, in the niches, 
interact with microenvironmental cells which, in turn, regulate EPC fate (Papayannopoulou, 2003). 
EPCs can be released from BM into PB through a process called mobilization. As aforementioned, 
EPCs are a rare population in PB, and the mechanisms that regulate their number are still unknown, 
although growth factors such as GM-CSF, granulocyte colony-stimulating factor (G-CSF), 
macrophage colony-stimulating factor (M-CSF), stem cell factor (SCF) and TGFβ could have a 
fundamental role (Pompilio et al., 2009). Both in physiological conditions, such as physical activity 
or endometrial reconstruction after menstrual cycle, and in pathological conditions, such as 
myocardial infarction and ischemic attack, EPC frequency in PB can increase (Massa et al., 2009). 
Although the phenomenon has extensively been studied, a mechanism that explains each phase of 
mobilization process has not been yet described. Possibly, a central role is played by GM-CSF and 
G-CSF (both widely used in hematology for the expansion and mobilization of hematopoietic stem 
cells in BM transplantation), by VEGF, whose administration increase EPC number and functional 
abilities (Asahara et al., 1999), and by the soluble form of the c-kit ligand, otherwise called stem 
cell factor (SCF). The latter requires the cleavage by MMP9 to become active and can interact with 
its c-kit receptor on EPCs, thus triggering the signalling cascade which stimulates EPC exit from 
BM (Heissig et al., 2002). MMP9 activity can also be increased by another key factor for the 
mobilization process, namely nitric oxide (NO). The expression of endothelial nitric oxide synthase 
(eNOS), for example, is enhanced by VEGF in BM stromal cells (Ribatti, 2007). Murohara et al. 
demonstrated that the impaired neovascularization in mice lacking eNOS was related to a defect in 
EPC mobilization (Murohara et al., 1998). Thus, within the BM niche, cytokines, chemokines, 
proteases and adhesion molecules converge in a complicated network of interaction in which every 
factor has an important role to determine EPC retention or mobilization (Papayannopoulou, 2004). 
This scenario has further been complicated by a recent model, according to which some cytokines 
might block EPC interaction with the surrounding stroma thereby enhancing their transendothelial 
migration. Little is known about this process, but some studies demonstrated that EPCs and murine 
BM progenitor cells are able to extravasate (Jin et al., 2006). Finally, integrins and their respective 
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ligands are involved in the EPC mobilization of progenitor cells. Human adult PB-derived EPCs 
express β2-integrins (Chavakis et al., 2005; Wu et al., 2006). In vitro adhesion studies revealed that 
β2-integrins mediate the adhesion of human EPCs to mature endothelial cell monolayers (Chavakis 
et al., 2005). Additional studies demonstrated the role of β2 integrins for the homing and 
neovascularization capacity of EPCs in a murine model of myocardial infarction (Wu et al., 2006). 
The contribution of α4β1 integrin is more complex. In a recent study, the blockage of α4β1 integrin 
did not inhibit homing of EPCs to ischemic tissues, but increased mobilization of progenitor cells 
from the bone marrow and enhanced progenitor cell-mediated neovascularization in the context of 
ischemia (Qin et al., 2006). Nevertheless, the inhibition of α4β1-integrin significantly blocked 
adhesion and homing of bone marrow progenitor cells to sites of active tumor neovascularization in 
xenografted tumor models (Jin et al., 2006). A conceivable explanation for this discrepancy is that 
different integrins may play distinct context-specific roles (ischemic vs. tumor neovascularization) 
during EPC mobilization.  
EPC RECRUITMENT 
Homing is the biological process by which EPCs target their final destination, i.e. ischemic or 
damaged tissues or growing tumors. Homing to sites of active angiogenesis is finely regulated by a 
delicate interplay among chemokines, chemokine receptors, adhesion molecules, and proteases 
(Chavakis et al, 2008). While lymphocyte homing towards inflammation sites is a well known 
process, the homing of EPCs to sites of ischemia or tumor vascularization is less understood, even 
though these two processes share some common features. Several studies have, however, sought to 
elucidate how EPCs reach their target organ. For example, the SDF-1/CXCR4 axis has been shown 
to play a fundamental role in this context. This axis effectively involves the stromal derived factor-1 
(SDF-1) which binds his receptor on the surface of PM, the C-X-C chemochine receptor type 4 
(CXCR-4). EPCs express CXCR4 on their surface, and both CXCR4 and SDF-1 expression are up-
regulated under specific pathological conditions, such as ischemia (De Falco et al., 2004). 
Consistently, inhibiting the SDF-1/CXCR4 axis interferes with EPC homing to ischemic 
myocardium (Abbott et al., 2004); conversely, local SDF-1 overexpression enhances EPC homing 
and incorporation into ischemic tissues. Thus, it has been hypothesized that a SDF-1 gradient is 
generated from the ischemic site (more concentrated) to the PB (less concentrated), thereby 
favoring EPC recruitment to sites of active neovascularization. Sun et al. described a similar 
mechanism for EPC homing in different types of tumors (Sun et al., 2010). They found that SDF-1 
is involved in tumor development by attracting tumor cells to metastatic lesions, by recruiting BM-
derived hematopoietic stem cells and EPCs at both primary and secondary deposits, and possibly by 
favoring the establishment of cancer stem cells within the tumor microenvironment. 
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Finally, VEGF could also contribute to EPCs recruitment either directly or through an interaction 
with the SDF-1/CXCR4 axis (Zagzag et al., 2006). Similar to SDF-1, a VEGF gradient is 
established between the angiogenic site and the BM niche, thereby paving the way for EPC homing 
to their final destination. Thus, an intricate network of different factors also participates in EPC 
recruitment, but the molecular mechanisms through which they act are not completely clear yet. 
 
EPC DIFFERENTIATION 
As previously described, EPC proliferation, migration and differentiation, are regulated by several 
growth factors, cytokines, and chemokines, but the fine mechanisms governing these processes are 
still unclear. VEGF and its receptors play the most prominent role in endothelial differentiation 
during embryogenesis. It has been demonstrated that fibronectin favors VEGF-induced EPC 
differentiation with a rather complex mechanism. First, VEGF binds to fibronectin heparin-II 
domain. Second, this interaction leads to the physical association between VEGFR-2 and α5β1 
integrins, thus triggering the intracellular signalling pathways responsible for EPC differentiation 
(Wijelath et al., 2006). Subsequently, Li et al. and Zhu et al. reported that AMP-activated protein 
kinase (AMPK) also plays an important role in EPC differentiation by mediating VEGF-induced 
eNOS activation (Li et al., 2008; Zhu et al., 2011). This observation was supported by subsequent 
studies focusing on the involvement of the Krüppel-like transcription factor (KLF) family in EPC 
differentiation. KLF is a central regulator of endothelial proliferation, differentiation and 
development (McConnell and Yang, 2010). Recent work has demonstrated that KLF2 is activated 
by VEGF in an AMPK-dependent manner and controls EPC differentiation by inducing the 
expression of endothelial markers, down-regulating the stem/progenitor marker c-kit, augmenting 
eNOS expression and improving tube formation capacity (Song et al., 2013).  
Finally, shear stress has also been investigated as mediator of EPC differentiation. Shear stress is 
the tangential force of the flowing blood on the endothelial surface of the blood vessel and is 
necessary for maintaining cardiovascular homeostasis. In particular, shear stress subserves an 
important role in angiogenesis, in vascular tone control and in vascular remodeling. Endothelium 
exposed to shear stress undergoes cell shape changes, alignment and microfilament network 
remodeling in the direction of flow. Moreover, shear stress causes mature ECs to express and 
secrete a multitude of anti-atherogenic, anti-thrombotic and anti-inflammatory proteins, and to up-
regulate eNOS and NO production. Similarly, shear stress also influences EPC differentiation into 
mature ECs by promoting adhesion, migration, proliferation, tube formation and expression of 
mRNAs encoding for endothelial-specific genes, such as VEGFR-1, VEGFR-2, VE-Cadherin and 
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Tie-2. Finally, shear stress has been demonstrated to induce EPCs differentiation by activating 
VEGFR-2 and the PI3K/Akt/mTOR pathway (Obi et al., 2012). 
In conclusion, several different factors, either biological or mechanical, can influence and regulate 
EPC differentiation, but the specific pathways underlying the process are still largely unknown. 
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ANGIOGENESIS AND CANCER 
Angiogenesis can restart in adult life, not only in physiological conditions, but also in pathological 
ones, for example during phlogosis, ischemic diseases and cancer. Since ‘70s, Judah Folkman has 
documented that a tumor cannot expand fed only by diffusion, but it needs a vascular network 
which is necessary for growth, invasion and metastatization (Folkman, 1992). Furthermore, in last 
decades, a large number of studies focused on the importance of tumor microenvironment 
(basement membrane, immune cells, capillaries, and extracellular matrix) and on the interactions 
between cancer cells and normal stromal cells. As an example, cancer associated fibroblasts (CAF), 
found in tumor microenvironment, have been shown to favor tumor progression by promoting 
interactions between cancer cells, ECs, perycites, epithelial and inflammatory cells, through the 
secretion of specific growth factors (Kalluri and Zeisberg, 2006).  
Figure 5. Cancer-associated fibroblast and tumor-associated macrophages: interactions and 
cytokines release (Shih et al., 2006). 
 
Among inflammatory cells, macrophages can be found as a major component of the leukocytic 
infiltrate. It has been demonstrated that they are also present with an active role in growing tumors, 
in which they are referred to as tumor associated macrophages (TAM) (Figure 5). Similarly to CAF, 
TAM can interact with cancer cells and stimulate the transcription of genes important for the 
regulation of cell cycle, adhesion to extracellular matrix, signal transduction, inflammation and 
angiogenesis. All together, the interactions between CAF, TAM, cancer cells and other cells 
belonging to tumor microenvironment result in cancer progression, invasion and metastatization 
(Shih et al., 2006). The latter process, however, cannot take place in the absence of a supporting 
vascular network. The transition from in situ carcinoma to a highly vascularized tumor has indeed 
been termed “angiogenic switch” and allows cancer cells to spread to distant sites thereby causing 
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patients death. The angiogenic switch also allows tumor perfusion which brings nutrients, oxygen 
and several growth factors, proteinases and cytokines that exert a paracrine effect on tumor cells, 
while at the same time removing their catabolic waste. Accordingly, some human carcinomas can 
persist in situ for months to years, but they are not able to growth more than 1-2 mm3 without 
connecting to peripheral circulation because of the physical constraints imposed by nutrient 
diffusion rates. Under these conditions, tumor size is shaped by a delicate balance between cell 
proliferation and apoptosis. In growing tumors, however, microscopic areas of intense angiogenesis 
can flank hypo-vascularized areas (Ribatti et al., 2007). When the angiogenic switch occurs, a thick 
capillary network surrounds and penetrates the tumor to sustain cancer growth and metastatization. 
The angiogenic switch is activated when the balance between pro- and anti-angiogenic factors tips 
in favor of the former.  
Tumor vasculature is completely different from normal vasculature, both in structure and function; 
the chaotic vessels organization leads to highly vascularized regions in close proximity of vessel-
poor areas. Neoplastic vasculature is tortuous, irregular, and lumens can vary from abnormally wide 
to really thin. Every layer of the vessel wall is abnormal and also ECs do not display the classical 
cobblestone shape and often lose their interconnections. Basal membrane thickness and 
composition are irregular and fewer hypocontractile mural cells cover tumor vessels. All these 
abnormalities result in an irregular perfusion that impairs nutrients, oxygen and drugs delivery. In 
order to improve vascularization, and consequently nutrients and oxygen supply to the growing 
tumor, vasculogenesis and angiogenesis are reactivated, thereby giving rise to the angiogenic 
switch. In the tumoral site, the angiogenic switch consists in the formation of an intricate network 
of tumor-associated vessels that ensure the access to peripheral circulation and sustains cancer 
growth and metastatization (Hanahan and Folkman, 1996). In a simplified largely accepted model, 
neoangiogenesis takes place when VEGF stimulates ECs to synthesize and secrete MMPs which, in 
turn, are able to break the basal membrane of capillaries to which ECs belong. Thereby, ECs tear 
off the vascular wall and can migrate towards the extracellular matrix where they can proliferate 
and give rise to new vessels that supply the growing tumor with blood, nutrients, and oxygen. 
During this process, a number of accessory cells like TAM, CAF, mural cells and pericytes are 
recruited to secrete growth factors and cytokines that participate to produce new basal membrane 
and extracellular matrix. The whole process is regulated by inducer and inhibitor factors (Bergers 
and Benjamin, 2003). Two fundamental examples of these regulators are, respectively, VEGF and 
TSP-1. VEGF expression is enhanced by tissue-hypoxia and by some oncogenes, such as Ras and 
Myc. VEGF role in angiogenesis and VEGF as potential target of antineoplastic therapies will be 
discussed in next paragraphs. Conversely, TSP-1 has an important inhibitory effect on neovessel 
formation and on angiogenic switch. It binds its receptor on the ECs and triggers a signalling 
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pathway that inhibits angiogenesis. Besides VEGF and TSP-1, in the last few years, dozens of 
angiogenesis regulators have been identified. They are involved in controlling not only tumor, but 
also physiological angiogenesis during tissue remodeling and wound repair; such inhibitors may act 
as intrinsic barriers to induction of angiogenesis in incipient neoplasia (Hanahan and Weinberg, 
2011). The up-regulation of VEGF as well as other pro-angiogenic growth factors is solicited by the 
decrease in oxygen tension (pO2) that features growing tumors. The drop in pO2 is sensed by the 
hypoxia-inducible factor-1α (HIF-1α), a transcription factor controlling the expression of genes 
encoding for several cytokines and growth factors, such as VEGF, epidermal growth factor (EGF), 
basic fibroblast growth factor (bFGF), insuline-like growth factor-2 (IGF2). They can be released 
into blood circulation to stimulate adjacent capillaries to sprout towards avascular neoplasia and 
also to promote BM niche to switch from a quiescent status to a pro-angiogenic one (Moccia and 
Poletto, 2014). Once the angiogenic process is activated, the sequence of biological events can 
slightly differ among different types of tumor, stating that not every type of neoplasia depends on 
enhanced angiogenesis. Some tumors, indeed, as pancreas adenocarcinoma, show no strict 
dependency on angiogenesis as opposed to dependency on the secretion of cytokines and growth 
factors by stromal cells, especially in later stages. Conversely, many other tumors, such as kidney, 
breast, and colon cancer, are hyper-vascularized and show an abnormally large number of blood 
vessels attached to them. In conclusion, the angiogenic switch is essential for the first steps of the 
tumor growth but then, a complex regulation system, which can involve both tumoral and stromal 
cells, co-operating for neoplastic vascularization, can take over tumor progression. 
 
EVIDENCES IN FAVOUR TO EPC CONTRIBUTION TO TUMOR VASCULATURE 
The capability of cancer cells to intravasate into peripheral circulation and disseminate to remote 
organs is exacerbated by the well known chaotic disorganization of tumor vessels. These are 
featured by a number of morphological, cellular, and molecular abnormalities that all together 
concur to shape a dilated, tortuous, and hyperpermeable microvascular network inside the neoplasm 
(Dudley, 2012; Moccia and Poletto, 2014). The remarkable heterogeneity in tumor endothelium is 
dictated by three main mechanisms, which are not mutually exclusive, but may interact to produce 
aberrant endothelial cells: 1) the cross-talk with the surrounding microenvironment - featured by 
hypoxia, low pH, disorganized basement membrane, elevated interstitial fluid pressure, enrichment 
in growth factors and cytokines - which may impart both genetic and epigenetic modifications to 
tumor endothelial cells (TECs); 2) the vascular bed of origin, which conveys a site-specific 
epigenetic footprint to endothelial cells sprouting towards the neoplastic lesion; and 3) the 
contribution of additional mechanisms to tumor vascularization, including vasculogenic mimicry, 
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intussusceptive angiogenesis, vessel co-option, recruitment and engraftment of haematopoietic and 
endothelial progenitor cells (Dudley, 2012; Aird, 2012). A growing number of studies have now 
established that the concerted interaction between local endothelial cells and circulating EPCs is 
key to the angiogenic switch in tumor growth and metastatic progression (Moccia and Poletto, 
2014; Gao et al., 2009; Nolan et al., 2007). The angiogenic switch is turned on when the delicate 
balance between pro- and anti-angiogenic factors is tipped in favour of neovessel formation by 
tumor microenvironment. This process is regulated by HIF-1α, activated under the hypoxic 
conditions of a growing tumor thus driving the expression of VEGF, EGF, bFGF, and SDF-1α 
(Carmeliet and Jain, 2011; Moccia et al, 2012). Once released into circulation, these soluble factors 
promote local angiogenesis by stimulating nearby endothelial cells to sprout towards the neoplasm; 
at the same time, they mobilize BMDCs and target them to the nascent vasculature (Gao et al., 
2009; Moccia and Poletto, 2014; Coghlin and Murray, 2010). Indeed, a remarkable pro-angiogenic 
activity has been acknowledged to several populations of BM-derived haematopoietic cells, such as 
CXCR4+ VEGFR1+ hemangiocytes, Tie2-expressing monocytes, CD45+/CD11b+ myeloid cells, 
F4/80+ CD11b+ tumor-associated macrophages (TAMs), GR1+ CD11b+ “myeloid-derived 
suppressor cells” (MDSCs), and infiltrating neutrophils and mast cells (Gao et al., 2009; Patenaude 
et al., 2010). These cells sustain tumor growth perivascularly by paracrine liberation of growth 
factors and cytokines, but do not incorporate within vessel lumen. Conversely, EPCs may provide 
the building blocks for neovessel formation as well as secrete instructive signals for neighbouring 
endothelial cells (Gao et al., 2009; Moccia, Dragoni et al., 2014; Moccia et al., 2014). The earlier 
demonstration that EPCs are involved in tumor angiogenesis was provided by Lyden and 
coworkers, who found that BM transplantation rescued growth and metastatization of two distinct 
syngenic tumor models (B6RV2 lymphoma and Lewis lung carcinoma or LLC) xenografted in the 
angiogenic defective Id1+/+ Id3-/- mutant mice (Lyden et al., 2001). Tumor vascularization under 
these conditions was associated to the recruitment of VEGFR-1+ myeloid cells and VEGFR-2+ 
EPCs from reconstituted BM. The same authors documented that the engraftment of β-
galactosidase-positive (lacZ) BM from Rose-26 mice, which express lacZ in all tissues, 
recapitulated angiogenesis in Id1+/+ Id3-/- mice implanted with B6RV2 tumors. Importantly, 
histological examination disclosed lacZ+ vessels in tumors inoculated for at least 14 days, while 
90% of lacZ+ vessels were also stained for von Willebrand factor (vWF) a typical endothelial 
marker; this latter feature confirmed that BM-derived cells were intraluminally incorporated within 
tumor vasculature (Lyden et al., 2001). Subsequently, fluorescence in situ hybridization (FISH) of 
sex chromosomes in individuals who developed cancer after BM transplantation with donors of the 
opposite sex, detected BM-derived endothelial cells throughout tumor vasculature, their percentage 
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ranging from 1% to 12% depending on the malignancy (Peters et al., 2005). More recently, Nolan 
and coworkers used BMDCs isolated from GFP+ mice and injected into lethally irradiated syngenic 
wild-type recipient to investigate EPC contribution to tumor angiogenesis (Nolan et al., 2007). 
Reconstituted animals were xenografted with three distinct tumor types, i.e. LLC, B6RV2 and 
melanoma, and then examined at various stages of tumor development by using endothelial (VE-
cadherin, CD31, endoglin, and VCAM), haematopoietic (CD11b, CD45RB, CD41) and progenitor 
(CD133) markers. GFP expression, in turn, ensured BM origin of vessel cells. These authors first 
found that BM-derived GFP+ cells were recruited at the periphery of LLC at the early stages of 
tumor growth (days 4-6) prior to the sprouting of endothelial cells from nearby capillaries. These 
cells were identified as EPCs based on their morphological and phenotypic characterization. 
Accordingly, they presented with low levels of CD31 and uniformly expressed VE-cadherin, which 
is restricted at adherens junctions between two adjacent cells in mature endothelium. Additionally, 
these cells were endowed with the progenitor cell marker, CD133, and lacked all the 
haematopoietic antigens for which they were probed. When LLC tumors were inspected at later 
stages (6-8 days), they showed chimeric vessels comprising both non-BM-derived cells and BM-
derived GFP+ CD31+ VE-cadherin+ cells with all the features of a typical mature endothelial cells: 
i.e. spindle-line morphology, high surface expression of CD31, VE-cadherin staining at the 
intercellular adherens junctions, and absence of haematopoietic antigens. Importantly, high 
resolution stereo-confocal microscopy confirmed that GFP+ cells did not occupy a perivascular 
location, while optical sectioning of multiple z-stacks (30 µm resolution) displayed that BM-
derived endothelial cells possess a single nucleus and that CD31 and GFP signals derive from the 
same individual cell. This proved that tumor endothelial cells could actually originate from BM-
mobilized EPCs. Intriguingly, flow cytometric analysis revealed that the percentage of BM-derived 
EPCs (GFP+ VE-cadherin+ CD31low CD11b−) decreases from 25%-35% in the early phase of 
tumor development (4-6 days) to 6-8% at later stages (6-8 days), while the fraction of local non-
BM-derived endothelial cells (GFP- VE-cadherin+ CD31low CD11b−) increased to 65%-75% at 
days 10-14 (Nolan et al., 2007). Finally, luminal incorporation of BM-derived endothelial cells was 
probed by the systemic administration of fluorescent isolectin IB4 and flow cytometric analysis of 
isolectin IB4+ CD31+ GFP+ CD11b- cells: this manoeuvre permitted to conclude that, at day 6, 31% 
of luminally incorporated endothelial cells derived from BM. The same results were found in the 
other tumor types investigated in this study, namely B6RV2 lymphoma and melanoma, and in a 
transgenic breast cancer mouse model (MMTV-PyMT) (Nolan et al., 2007). In this model, the 
polyoma middle T antigen (PyMT) oncogene is expressed under the control of the mouse mammary 
tumor virus promoter (MMTV) to achieve the neoplastic transformation of mammary epithelium 
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(Fantozzi and Christofori, 2006). Thus, EPCs play a crucial role during the initial steps of tumor 
vascularization. The MMTV-PyMT transgenic mice were further exploited to assess EPC 
contribution to the dynamics of vessel assembly that turns dormant micrometastases into letal 
macrometastases (Gao et al., 2008). By using the same procedure described in their seminal paper 
(Nolan et al., 2007), Gao and coworkers focussed on the angiogenic switch in lung metastases that 
spontaneously develop in this breast cancer model. They found that micrometastases formed by 
week 12 were poorly vascularised, as shown by the lack of CD31+ vessels. Nevertheless, 
macrometastases that appeared at week 16, were positive to CD31 staining and displayed luminally 
incorporated BM-derived GFP+ CD31+ endothelial cells in about 11% of neovessels (Nolan et al., 
2007). This means that EPCs home to micrometastatic foci and contribute to neovessel formation, 
thereby sustaining the macrometastatic transition. The low percentage of EPC engrafting suggested 
that, apart from a structural role, they drive the angiogenic switch in a paracrine manner. The same 
findings were obtained by analyzing lung metastases in LLC xenograft mice; by using this model, 
the authors further found that many BM-derived GFP+ cells are recruited to micrometastases, but 
confocal microscopy analysis revealed that only endothelial cells (GFP+ CD31+ Isolectin IB4+) 
integrated into neovessels. Conversely, HSCs adopted a perivascular location (Nolan, 2007). 
Importantly, the peripheral region of the lesion is the initial target of BM-derived EPCs (GFP+ VE-
cadherin+ CD31dim CD11b-), as detected by fluorescence-activated cell sorting (FACS) of the 
lungs bearing micrometastases (Nolan et al., 2007). More recently, Id1 was identified as a putative 
EPC marker in BM-derived GFP+ VE-cadherin+ EPCs, where it drives the egression into peripheral 
circulation (Nair et al., 2014), but not in other BM-derived GFP+ myeloid cells (Mellick et al., 
2010). This feature might explain the defective angiogenic process observed in Id1-/- mutants (see 
also below). The use of Id1 promoted to drive GFP expression enabled Mellick and coworkers to 
selectively track EPC homing from BM to LLC tumors in the xenograft murine model employed in 
their previous work (Nolan et al., 2007; Gao et al., 2008). Again, high resolution microscopy 
revealed that BM-derived Id1+/GFP+ VE-cadherin+ CD31low EPCs targeted the periphery of early 
nonvascularized tumors (days 6-8). Luminally incorporated GFP+ CD31+ Isolectin IB4+ CD11b- 
mature EPCs were then detected in about 9% of tumor neovessels within later tumors (days 8-12). 
Along with many other parallel studies, these reports reinforced the concept that EPCs sustain the 
angiogenic switch in primary tumors and micro-to-macrometastatic transition at secondary lesions. 
An alternative approach consisted in assessing the engraftment and contribution of exogenous EPCs 
to tumor development in human xenograft models, including those for renal cellular carcinoma 
(RCC), hepatocellular carcinoma, and LLC (Asahara et al., 1999; H. Zhu et al., 2012; Ahn et al., 
2010; Yu et al., 2014). Unlike the previous investigations, however, these studies failed to validate 
the endothelial phenotype of the injected cells, by relying on rather unspecific markers (i.e. CD133, 
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CD34, VEGFR-2) that also feature HSCs. More recently, human ECFCs, which are regarded as 
truly endothelial precursors, were probed for their ability to specifically home to sites of tumor 
angiogenesis in mice bearing an array of distinct cancer types. For instance, upon intravenous 
injection into lethally irradiated mice, DiI-labelled ECFCs target LLC lung, but not kidney or liver, 
metastases; herein, they are mainly found at the periphery, rather than in the centre, and integrate 
within neovessels, albeit most of them adopt a perivascular location (Wei et al., 2007). 
Subsequently, Bieback and coworkers evaluated the extent of ECFC recruitment to rat C6 glioma 
xenograft, which is the most suitable model for the study of glioblastoma multiforme. By using the 
dorsal skinfold chamber model associated to intravital multi-fuorescence videomicroscopy, they 
found that DiI-stained ECFCs strongly interacted (adhesion and extravasation) with tumor 
vasculature, while human umbilical vein endothelial cells (HUVECs) and CD34+ MNCs were much 
less active (Bieback et al., 2013). These preliminary findings lend strong support to the tenet that 
ECFCs represent the most suitable subtype to unveil the molecular mechanisms driving EPC-based 
tumor neovascularization (Moccia Dragoni et al., 2014; Moccia Berra-Romani,et al., 2014; Moccia 
et al, 2012; Yoder and Ingram, 2009). 
Figure 6. Mechanism of tumor vascularization by EPCs (Moccia and Poletto, 2014). 
 
HOW TO SOLVE THE CONTROVERSY ABOUT EPC CONTRIBUTION TO TUMOR 
VASCULARIZATION? 
Despite the undoubted evidence in favour of EPC involvement in tumor growth and metastatization, 
several authors questioned their participation to the angiogenic switch (Patenaude et al., 2010; 
Yoder and Ingram, 2009). This is why several studies failed to evidence a measurable amount of 
luminally incorporated EPCs within tumor vessels. For instance, De Palma et al. transduced 
BMDCs with lentiviral vectors expressing the GFP gene under the control of the specific 
endothelial Tie2 promoter, which was followed by BM implantation into several subcutaneous 
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tumor model (De Palma et al., 2003). High resolution microscopic inspection detected only rare 
GFP+ CD31+ endothelial cells in tumor cells, which were instead abundant of GFP+ CD45+ CD11b+ 
CD31- monocytes and pericyte progenitors, with a preferential perivascular location (De Palma et 
al., 2003). Subsequently, Göthert et al. (Göthert et al., 2004) generated an endothelial-specific 
inducible transgenic model to assess the BM origin of tumor endothelium. The basic helix-loop-
helix transcription factor stem cell leukemia (SCL) is crucial to both haematopoiesis and 
vasculogenesis: several enhancers have been identified within the murine SCL locus that direct 
reporter gene expression in either endothelial cells (5’ promoter) or early HSCs (3’ promoter). In 
this study, the 5′ endothelial enhancer was exploited to obtain endothelial-specific expression of the 
tamoxifen-inducible recombinase Cre-ERT (endothelial-SCL-Cre-ERT). These mice were then 
intercrossed with Cre reporter strains (R26R) in which lacZ or enhanced yellow fluorescent protein 
(EYFP) were expressed following Cre-dependent recombination. Tamoxifen administration enabled 
to detect endothelial lacZ staining in newly formed LLC and B6RV2 vasculature in these animals. 
However, when wild type mice were subjected to BM transplantation from endothelial-SCL-Cre-
ER(T); R26R littermates before tumor inoculation, no lacZ staining appeared in neovessels on 
tamoxifen administration. These data supported the notion that local, but not BM-derived, 
endothelial cells support cancer growth (Göthert et al., 2004). Other studies also could not 
demonstrate EPC incorporation in the endothelial layer of several primary and metastatic tumors 
(Wickersheim et al., 2009; Machein et al., 2003; Purhonen et al., 2008). An additional proof of 
evidence that has been carried against EPC contribution to the angiogenic switch is their rarity in 
some tumor models, which display only 1-2% of EPCs-derived neovessels. The passionate debate 
arose about this issue might be easily reconciled when taking a few key considerations in account. 
As recalled by Gao et al. (Gao et al., 2009) and in (Yoder and Ingram, 2009), EPCs are recruited to 
tumor periphery prior to vasculature formation (Nolan et al., 2007; Gao et al., 2008), acquire an 
endothelial phenotype and are luminally engrafted into a subset of neovessels in early tumors. At 
later stages, these chimeric structures are diluted/replaced by local host-derived sprouting vessels, 
which would explain the low involvement described in already developed tumors by other 
investigators (De Palma et al., 2003; Göthert et al., 2004; Purhonen et al., 2008; Duda et al., 2006). 
Accordingly, De Palma et al. (De Palma et al., 2003) assessed EPC incorporation at week 4, while 
Göthert et al. (Göthert et al., 2004) at 14 days post-implantation, which are fully compatible with 
the data described in (Nolan et al., 2007) and (Gao et al., 2008). EPC recruitment preceding the 
engagement of host vasculature suggests that these cells play a key role in the stimulation of non-
BM-derived endothelial cells sprouting from nearby capillaries. Nevertheless, by using two distinct 
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transgenic mosue models of de novo tumorigenesis, i.e. Rip-Tag5 that develops pancreatic islet 
cancer and Alb-Tag that develops liver cancer, Spring et al. (Spring et al., 2005) could not identify 
BM-derived GFP+ endothelial cells in pre-neoplastic lesions, while up to 30% of tumor-associated 
vessels were green at more advanced stages. This report highlight another feature that should be 
borne in mind when discussing the role served by EPC during tumor development, i.e. the stage 
specific engagement of EPC might depend on tumor type (Gao et al., 2009). More in general, the 
overall EPC contribution to the angiogenic switch could be tumor-type dependent. This hypothesis 
is corroborated by the work carried out on mice heterozygous for the tumor suppressor Pten 
(Pten+/−), that exhibit a wide array of malignancies, such as uterine carcinomas (UC), 
pheochromocytomas, lymph hyperplasia, and prostate interepithelial neoplasias. Ruzrinova et al. 
(Ruzinova et al., 2003) discovered that Pten+/- spontaneous lymph hyperplasia lacked BM-derived 
EPCs, identified as lacZ+ VEGFR-2+ cells in animals transplanted with BM from Rosa 26 mice 
expressing lacZ in all their tissues, while these cells were easily detectable on 15%-20% of UC 
neovessels. Finally, it is worth of recalling that the field has long been flawed by the wrong 
interpretation of the term EPC (Moccia et al., 2014; Yoder and Ingram, 2009; Basile and Yoder, 
2014). As already mentioned throughout this work, several studies claimed to evaluate EPC 
frequency in cancer patients or to evaluate their contribution to tumor growth and development in 
xenograft models (Asahara et al., 1999; Jung et al., 2012; H. Zhu et al., 2012); yet, these reports 
identified EPCs based on the selection of a panel of surface antigens that is inadequate and totally 
unreliable to detect truly endothelial progenitors (Gao et al., 2009; Moccia et al., 2014; Moccia et 
al., 2014; Yoder, 2012). These cells were more likely to belong to the haematopoietic lineage that 
may certainly sustain the angiogenic switch in a paracrine manner, but does not provide structural 
support to tumor vasculature. On the other hand, BM-derived EPCs are essential for cancer 
development and metastatization as evident in Id knock-out (KO) mice that fail in mobilizing these 
progenitors from the stem cell niche (Lyden et al., 2001; Li et al., 2004). These xenograft models 
either display rapid tumor regression (Lyden et al., 2001; Mellick et al., 2010) or a significantly 
delayed cancer progression (Li et al., 2004). More recently, Gao et al. (Gao et al., 2008) found that 
acute and conditional short hairpin RNA (shRNA)-mediated genetic ablation of Id1 in BM-derived 
EPCs do not decrease the number of micro-metastatic lesions, but prevent the macro-metastatic 
transformation in LLC xenografts (Gao et al., 2008). Subsequently, Mellick et al. (Mellick et al., 
2010) used Id1 proximal promoter (pr/p) to drive the expression of the suicide gene herpes simplex 
virus (HSV)-thymidine kinase (tk) in BM-derived EPCs; this manoeuvre led to a notable reduction 
in EPC frequency and impaired tumor (LLC and B6RV2) growth and vascularization. By using the 
same strategy, Plummer et al. (Plummer et al., 2013) genetically suppressed the expression of the 
 25 
miRNA-processing enzyme, Dicer, in BM, thereby achieving the decrease in circulating EPCs, 
tumor (LLC and breast cancer) size and vessel density. Therefore, there is ample experimental 
evidence to conclude that truly endothelial precursors play a crucial role in cancer development and 
metastatization. 
 
VEGF AS TARGET FOR ANTI-ANGIOGENIC TREATMENTS 
VEGF stimulates angiogenesis and EPC mobilization by binding to VEGFR-2, also called KDR in 
humans and Flk-1 in mice, thus triggering a complex intracellular signalling cascade (Potente et al., 
2011). The downstream mediators of VEGFR-2 include, but are not limited to: 1) phospholipase Cγ 
(PLCγ), which may either lead to an increase in intracellular Ca2+ concentration ([Ca2+]i) or engage 
the protein kinase C (PKC/Ras/MEK/MAPK cascade, 2) cytosolic PLA2, which is activated upon 
extracellular signal-related kinase (ERK)-mediated phosphorylation and controls PGI2 production; 
3) phosphoinositide 3-kinase (PI3K), which in turn recruit the protein kinase B (PKB)/Akt pathway 
via an increase in phosphatidylinositol-3,4,5-trisphosphate (PIP3) to activate endothelial nitric oxide 
(NO) synthase (eNOS) and inhibit B-cell lymphoma 2 (Bcl-2)-associated death promoter 
homologue (BAD) and Caspase 9; 4) p21-activated protein kinase-2 (PAK-2), which is responsible 
for the subsequent activation of both Cdc42 and p38 MAPK; and 5) focal adhesion kinase (FAK) 
and its substrate paxillin. It is, however, worth of noting that most of these studies have been carried 
out on normal ECs, while the signalling pathways downstream VEGFR-2 in EPCs are less clear. 
Nevertheless, its tyrosine kinase activity is druggable and VEGF quickly became the main target of 
a myriad of anti-angiogenic therapies over the last few years. US Food and Drug Administration 
(FDA) has approved for clinical use some of these anti-angiogenic anti-VEGF drugs. The anti-
VEGF monoclonal antibody Bevacizumab (Avastin) has been approved for therapy in combination 
with chemotherapy for several different types of tumors as non-squamous non-small cell lung 
cancer, colorectal cancer and metastatic breast cancer. Another class of FDA approved drugs is 
represented by pan-VEGFR tyrosine kinase inhibitors (TKIs), such as Sunitinib (Sutent), Pazopanib 
(Votrient) for metastatic RCC, Sorafenib (Nexavar) for metastatic RCC and unresectable 
hepatocellular and Vandetanib (Zactima) for medullary thyroid cancer. In general, VEGF blockade 
prolongs progression-free survival and overall survival of cancer patients in the range of weeks to 
months. Several mechanisms could be used by VEGFR inhibitors to reach a clinical benefit: at first, 
these drugs could block vascular sprouting and BM-derived cells homing, thus inhibiting tumor 
vessel expansion. Second, they can produce a regression of pre-existing tumor vessels and deprive 
ECs of VEGF to survive, thereby sensitizing ECs to chemotherapies and irradiation. Third, a 
normalization of abnormal tumor vessel restoring a physiological vasculature can be another 
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mechanism (Goel et al., 2011). About the third point, preclinical studies have shown that anti-
VEGF therapy changes tumor vasculature towards a more "mature" or "normal" phenotype. This 
"vascular normalization" is characterized by attenuation of hyperpermeability, increased vascular 
pericyte coverage, a more normal basement membrane, and a resultant reduction in tumor hypoxia 
and interstitial fluid pressure. All these factors, in turn, can lead to an improvement of different 
factors as the metabolic profile of the tumor microenvironment, the delivery and efficacy of 
exogenously administered therapies, the efficacy of radiotherapy, and the reduction in number of 
metastatic cells shed by tumors into circulation in mice. A lot is known about this mechanism but it 
needs surely future studies (Goel et al., 2011). It has to be taken in mind that VEGFR-inhibitors act 
not only on the structure and function of tumor vasculature and ECs, but also on every kind of cells 
expressing VEGFR-2. EPCs express VEGFR-2 on their surface, which allows them to engraft 
within nascent vessels, proliferate and differentiate in mature ECs. Studies on xenograft models of 
LLC or B6RV2 tumors demonstrated that VEGFR-2 inhibition through a neutralizing antibody or a 
specific short hairpin RNA blocks tumor vascularization and growth; these results led to the 
suggestion that targeting VEGFR-2 could prevent EPCs stimulation in cancer patients (Lyden et al., 
2001; Mellick et al., 2010). Despite the encouraging result of preclinical studies, the oncological 
clinical practice revealed some unexpected limits of VEGFR inhibitors which depend on the poor 
knowledge about the fine mechanisms regulating tumor neoangiogenesis. Drugs had not the 
expected effects on progression-free survival which showed only a modest increase, and on overall 
survival. Furthermore, some patients are intrinsically refractory or develop resistance; therefore, a 
lot of research group started studying the possible mechanisms underlying patient resistant to drugs. 
Some of the resistance mechanisms to anti-VEGFR drugs are described below.  
- VEGF-independent vessel growth: tumors can release alternative growth factors including FGF, 
epidermal growth factor (EGF), and placental growth factors (PlGF) which can replace VEGF 
functions on cellular stroma and cause a resistance to VEGFR-inhibitors; 
- Stromal cells: all cells belonging to tumor stroma, including TAMs and CAFs, can produce other 
proangiogenic factors and recruit BM-derived cells; 
- ECs instability: it is clear that tumor ECs acquire morphological, functional and genetic 
differences as compared to normal endothelium. They can display chromosomic aberrations, 
higher proliferative potential, apoptosis resistance and lower sensitivity to cytotoxic drugs. 
Chromosomic alterations can also involve VEGFR-2 and, therefore, blocking its responsiveness 
to treatment; 
- Vascular independence: tumor cells are able to survive in the hypoxic tumor environment, with a 
consequent reduced vascular dependence that impairs the anti-angiogenic response. Moreover, 
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HIF-1α is able to render ECs resistant to irradiation. Some tumors also have a hypovascular 
stroma, but they can metastasize through the lymphatic vessels and the process cannot be blocked 
by anti-angiogenic treatments.  
- Sprouting-independent vessel growth: some tumors use alternative mechanisms for vessel 
development, as vasculogenic mimicry, intussusceptive angiogenesis and vessel cooption; 
 
These alternative mechanisms of tumor vessel growth do not necessarily require VEGF and are, 
therefore, insensitive to classic anti-VEGF inhibitors (Potente et al., 2011; Vasudev and Reynolds, 
2014). EPC-mediated vascularization may certainly be included among these alternative modes of 
tumor expansion and metastatisation. Not only does their earlier mobilization from bone marrow 
sustain the angiogenic switch that promotes metastatic progression (see above); a delayed burst of 
EPC is induced by cytotoxic drugs and VDAs, thereby inducing the well known phenomenon of 
acquired resistance that leads to patient death despite for continuous treatment (Moccia and Poletto, 
2014). Most, if not all, the studies assessing the role of VEGFR-2 in EPC proliferation and 
recruitment to tumor site, have been conducted on mice xenografted with human cancers and 
injected with EPCs obtained by normal, i.e. healthy donors. As VEGF signalling is functional in 
these cells (Dragoni et al., 2011; Dragoni et al., 2013; Turtoi et al., 2012; D. Yu et al., 2014), it is 
not surprising that blocking VEGFR-2 prevents EPC activation and causes tumor shrinkage in these 
pre-clinical settings. It is conceivable that only EPCs deriving from oncological patients should be 
employed to understand whether VEGFR-2 is a suitable target to suppress EPC recruitment in these 
patients (Moccia and Poletto, 2014).  
 
RENAL CELL CARCINOMA (RCC): A PERFECT MODEL FOR STUDYING 
ANGIOGENESIS AND EPCs 
Renal cell carcinoma accounts for the 2.1% of all solid neoplasms in the adults with 271.000 new 
cases and 116.000 deaths estimated in 2008. Male sex is more frequently involved with a 1.5:1 ratio 
(167.000 new cases in men vs. 103.000 new cases in women); the age standardized risk for this 
neoplasm is 3.9 cases every 100.000 people-year, with a cumulative risk of 0.5 (Ferlay et al., 2010). 
Despite being still considered a rare tumor, kidney cancer is showing constantly increasing 
incidence, 2-3% increase every 10 years (in the US the incidence has grown of 126% from 1950 up 
to our days) (Mathew et al., 2002). Epidemiologic meta-analysis of case-control studies has shown 
correlation with possible risk factors, among all tobacco consumption and obesity (Dhote et al., 
2004). As far as we know, kidney cancer is a neoplasm highly dependent on angiogenesis: our 
knowledge on its cancerogenesis (despite we are not referring to a single entity, as we will discuss 
briefly) derives from genetic studies on hereditary syndromes in which RCC is a clinical 
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component. Patients affected by von Hippel-Lindau syndrome, who carry a mutation on von 
Hippel-Lindau (VHL) oncosuppressor gene, are more likely to develop emangioblastomas, tumors 
of the yalk sack, cranio-spinal emangioblastomas and clear cell renal cell carcinomas (the latter in 
35-45% of the cases) (Walther et al., 1995); some partial gene deletions show higher correlations to 
tumor development than complete gene deletions (Maranchie et al., 2004), enforcing the evidence 
VHL inactivation plays a crucial role in cancer development (despite the molecular picture of this 
tumor has been recently shown to be much more intricate as we tend to consider it, by the evidence 
of intra-tumor genetic heterogeneity) (Gerlinger et al., 2012). Malignant kidney cancer is a 
heterogeneous class of diseases which can be distinguished histologically according to the 2004 
World Health Organization classification (H. Sobin, 2003); the major histotypes represented have 
slightly different pathogenesis and clinical behaviour. The most common is represented by clear 
cell RCC, in the 70% of the cases (Eble et al., 2004), where the correlation with VHL alterations is 
striking, followed by papillary RCC (15 to 30% of the cases), where a second, highly relevant, 
cellular pathway is involved (represented by the hepatocyte growth factor – scatter factor (HGF/SF) 
/ c-Met axis), and chromophobe RCC, which has a less clinical malignancy than the others (Eble et 
al., 2004). A last less frequent feature to be considered, is represented by the sarcomatoid variant, 
which is not a proper RCC histotype by its own, but it is a histological component which 
complicates 1% to 8% cases of RCC, usually worsening the prognosis (Cangiano et al., 1999). RCC 
originates from malignant transformation of renal tubule cells. Inactivation of the VHL 
oncosuppressor gene, which encodes for a ubiquitin ligase responsible for the ubiquitinization of 
HIF-1α and HIF-2α, leads to their accumulation while they are actively overexpressed thanks to the 
hypoxic environment created by the tumor growth, promoting definitively a stimulus on cell 
survival, angiogenesis and metabolism (Lonser et al., 2003; Linehan, 2007; Cheng et al., 2009). 
Hypoxia is highly relevant in the oncogenesis of human neoplasms as is a putative mechanism for 
clonal selection. HIF family enhances the transcription of many receptor proteins such as c-Met and 
growth factors such as TGF-α, VEGF, PDGF-β, and CXCL12 (Lonser et al., 2003). VEGF and 
PDGF-β induction are likely to be involved in the extremely pronounced vascularization of RCC; 
VEGF among both is an active player in the angiogenic switch, and correlates to increased risk of 
metastatization and resistance to therapies (Ferrara, 2005). VEGF and PDGF-β favour the migration 
and proliferation of endothelial cells as well as create an autocrine/paracrine loop responsible for 
self manteinance of tumoral cells, being their receptors expressed on the tumoral cell surface, 
(Ferrara, 2005; Badalian et al., 2007; Rivet et al. 2008). RCC carcinoma has been considered an 
orphan disease up to the last decade, as the only treatment available was represented by inteleukin-2 
and interferon-γ (IFN-γ), whose efficacy has always remained under debate. The natural history of 
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this neoplasm started slightly to change with the introduction of new molecularly targeted agents, 
represented either by monoclonal antibodies or by small molecules tyrosine kinases. The majority 
of compounds used nowadays in the treatment of the metastatic disease act against the 
VEGF/VEGFR pathway, and the drugs represented in this group are Sorafenib, Sunitinib, 
Pazopanib, Axitinib and Bevacizumab. Sorafenib, a small tyrosine kinase inhibitor (TKI), has been 
the first compound registered for therapy in metastatic RCC (mRCC) and showed a significant 
improvement of PFS in actively treated patients as opposed to the placebo treated control group (24 
weeks vs 6 weeks) (Escudier et al., 2007). Sunitinib is a second TKI which showed improvement in 
PFS in the treated population in the registration study, as compared to an IFN-γ treated group 
(Motzer et al., 2007). Pazopanib and Axitinb are, instead, relatively recently developed compounds, 
which have been registered for usage in mRCC after their respective registrative studies (Sternberg 
et al., 2010; Rini et al., 2011). VEGF receptor is not the only possible therapeutic target: its ligand, 
VEGF itself, can be blocked by a further compound which acts on this pathway, Bevacizumab, a 
monoclonal antibody used in association with IFN-γ, registered soon after Sorafenib (Escudier et 
al., 2007; Rini et al., 2008). The therapeutic arena is occupied by two other small molecule 
inhibitors: Everolimus and Temsirolimus, which are acting on a different cellular pathway, the 
mammalian target of rapamycin (mTOR) (Amato et al., 2009; Hudes et al., 2007).  
From a quite recent era of no therapeutic options available, many compounds are nowadays 
available: the reality of everyday clinical use shows that none of those guarantees stable therapeutic 
success and the way in which they should be used (sequence, patient sub-group selection, possible 
combination) is still not clear and under investigation. 
The clinical world of RCC, despite an improvement in therapy, faces constantly the lack of new 
strategies to achieve longer and stable results. One emerging cellular mechanism, which is starting 
to be explored, is the role of EPCs in RCC oncogenesis and their intimate connection to 
angiogenesis. EPC is an interesting cellular type, since many evidences showed a possible 
involvement in kidney cancer tumorigenesis: their ratio to CEC is increased in VHL patients who 
developed RCC and in patients with sporadic RCC, differently from VHL patients who did not 
develop the tumor (Bhatt et al., 2011); EPCs are possible biomarker in RCC patients as they 
correlate with VEGF (Yang et al., 2012) and possibly promote angiogenesis from RCC adjacent 
tissues where they are abundant (Zhao et al., 2013; P. Yu et al., 2014). Moreover, the level of 
peripheral EPCs positively correlates with RCC prognosis, the mean frequency being statistically 
higher in stage III-IV RCC patients as compared to those with stage I-II (Yang et al., 2012). 
Second, the number of circulating EPCs augments upon surgical removal of the primary tumor if 
the disease relapses in the form of metastases in distant organs (Hernandez-Yanez et al., 2012). 
Third, BM-derived EPCs may engraft within tumor vasculature as demonstrated by Hill, who found 
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that RCC developing within a kidney allograft manifest Y-positive chromosome vessels within a Y-
negative tumor (Hill, 2010). Consistent with this finding, TECs harvested from human RCC tumors 
sub-cutaneously implanted into nude mice expressed the mouse stem cell antigen (Sca)-1 (Matsuda 
et al., 2010). In addition, the expression of CD133, a surface antigen that features BM-derived 
progenitors, was far more abundant in mouse TECs isolated from OSRC-2 (a well estabilished 
human RCC cell line) cell xenografts in immunodeficent mice than in normal endothelium (Akino 
et al., 2009). Altogether, these findings support the notion that RCC vascularization is sustained by 
endothelial committed cells released from the osteoblastic niche. Their putative role as biomarkers, 
as their possible involvement in cancerogenesis, make EPCs a very likely cell lineage to be 
explored by further investigations aiming at searching for new therapeutic options in the treatment 
of RCC. 
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PRO-ANGIOGENIC CALCIUM SIGNALLING 
Calcium (Ca2+) is the most widespread signalling molecule in both excitable and non-excitable cells 
across the phylogenic tree (Berridge et al., 2003). Unlike other intracellular messengers, Ca2+ is 
neither synthesized or metabolised, but is delivered to specific Ca2+-dependent decoders upon cell 
stimulation by chemical (e.g. hormones, transmitters, growth factors, and cytokines) and physical 
(e.g. shear stress, pulsatile stretch and osmotic swelling) stimuli. Each cell disposes of a unique 
pathway (or “toolkit”) of Ca2+-handling proteins that enables it to generate intracellular Ca2+ signals 
of a particular amplitude, duration, frequency, and spatial location (Berridgeet al., 2003). 
Consequently, the Ca2+ signature produced by each cell in response to a precise stimulus is able to 
control a multitude of cellular processes, ranging from fertilisation to programmed cell death 
(Sammels et al., 2010). For instance, transient (in the µsec range) elevations in intracellular Ca2+ 
concentration ([Ca2+]i) activate myocardial contraction, neurotransmitter release, and focal adhesion 
dynamics (Bers, 2008; Brini et al., 2014; Chen et al., 2013), while prolonged (in the minutes-to-
hours or days range) oscillations in [Ca2+]i control proliferation, differentiation, and gene expression 
(Dragoni et al., 2011). Ca2+ signals may be delivered as global Ca2+ spikes or may be restricted to 
nano- or micro-scoping domains emanating from the cytosolic mouth of Ca2+-releasing channels 
(Parekh, 2008). This local mode of signalling has the advantage to target Ca2+ precisely to a specific 
Ca2+-dependent effector among the many that are dispersed throughout the cell (Berridge et al., 
2003; Lam and Galione, 2013). Alternatively, Ca2+ waves may be transferred to adjacent cells by 
either paracrine or gap-junctional communication to coordinate multicellular processes, such as 
vascular tone regulation (Altaany et al., 2014) and wound repair (Moccia and Poletto, 2014). 
Evolution has developed a number of conserved Ca2+-binding sequences that transmit Ca2+ 
sensitivity to the proteins they belong to. The combination between the spatio-temporal of the Ca2+ 
signal with the differences in Ca2+ interaction kinetics among the known Ca2+-binding proteins 
allows this ubiquitous messenger to finely regulate highly specific intracellular processes (Clapham, 
2007). The best characterized Ca2+-binding domain is the EF-hand motif, that is found in a wide 
array of proteins accomplishing cellular functions as diverse as contraction (e.g. troponin C), 
apoptosis and disassembly of cell adhesions (e.g. calpain, calcium and integrin-binding protein 1, 
and S100 proteins), gene transcription (e.g. neuronal Ca2+ sensor proteins (NCS) and S100 proteins) 
and intracellular Ca2+ modulation (e.g. Stim1 and Ca2+-binding proteins (CaBPs)). Another widely 
diffused Ca2+-binding sequence is represented by the C2 domain, which gives Ca2+-sensitivity to 
protein kinase C (PKC), phospholipase A2 (PLA2) and phospholipase C (PLC), thereby regulating 
the exocytosis of secretory vesicles at synaptic terminals (Carafoli et al., 2001). In addition to 
directly activating the Ca2+-sensitive effectors, local Ca2+ signals may exert their influence event at 
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considerable distance (e.g. into the nucleus) by recruiting intermediary Ca2+ sensors, such as the 
promiscuous EF-hand-containing protein calmodulin (CaM) (Parekh, 2010). CaM, in turn, 
establishes a close correlation between the spatial-temporal pattern of the Ca2+ signal and the 
ensuing physiological response. The most important CaM-regulated effectors are Ca2+/CaM-
dependent kinases (CaMKI, CaMKII and CaMKIV), the phosphatase calcineurin, and the eNOS 
(Carafoli et al., 2001). Moreover, CaM may relocate into the nucleus, where it activates the cAMP 
response element binding protein (CREB), a transcription factor with an established role in 
neuronal plasticity and long-term memory consolidation in the brain. Alternatively, CaM may 
stimulate calcineurin to dephosphorylate the nuclear localization signals (NLS) of NFAT, thereby 
promoting its migration into the nucleus, where it binds to the cis-regulatory elements of its target 
genes. Finally, CaMKIV may phosphorylate the inhibitory protein, IkB, which retains nuclear-factor 
kappa B (NF-κB) into the cytosol by masking its NLS. As a consequence, IkB is targeted for site-
specific ubiquitination and proteolitic degradation, whereas NF-κB translocates into the nucleus 
(Alonso and García-Sancho, 2011). 
 
PRO-ANGIOGENIC Ca2+ SIGNALS IN MATURE ENDOTHELIAL CELLS 
Endothelial cells are not an exception to the widespread dependence on intracellular Ca2+ 
signalling. It has long been known that an increase in [Ca2+]i plays a key role in the intricate 
network of signal transduction pathways exploited by ECs to maintain cardiovascular homeostasis ( 
Mocciaet al, 2012). Being located at the interface between the vessel wall and circulating blood, 
they perceive a multitude of extracellular signals, conveyed both the chemical messengers (such as 
growth factors, cytokines, and autacoids) and mechanical forces (such as pulsatile stretch, shear 
stress, and changes in local osmotic pressure), through an armamentarium of membrane-bound 
receptors, each of which is capable of triggering an increase in [Ca2+]i. The spatio-temporal profile 
of the Ca2+ signal enables the stimulated endothelial cell to select the most suitable response to 
extracellular inputs, i.e. production of vasoactive mediators, such as nitric oxide (NO), prostacyclin 
(PGI2), hydrogen sulphide (H2S), endothelial-dependent hyperpolarizing (EDHF) and contracting 
(EDCF) factors, biosynthesis of von Willebrand factor and tissue plasminogen activator, control of 
intercellular permeability, nuclear factor of activated T-cells (NFAT) and NF-kB activation, gene 
expression, cell proliferation, angiogenesis, and wound repair (Munaron and Fiorio Pla, 2009; 
Mancardi et al., 2011; Moccia et al., 2012;Moccia et al., 2006; Piscopo et al., 2007). It has long 
been known that Ca2+ signals regulate angiogenesis by controlling all the key steps of vessel 
remodelling, including endothelial proliferation, permeability, motility, and interaction with the 
extracellular matrix. In particular, VEGF utilizes Ca2+ signalling to promote endothelial cell 
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proliferation and tubulogenesis both in vitro and in vivo (Moccia et al., 2012; Abdullaev et al. 
2008). The pro-angiogenic Ca2+ response occurs downstream of PLCγ activation and may adopt 
distinct patterns depending on the vascular bed of origin. PLCγ cleaves the phospholipid precursor, 
phosphatidylinositol 4,5-bisphosphate (PIP2), into two intracellular second messengers, i.e. inositol 
1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG). These two signalling intermediates activates 
two distinct modes of [Ca2+]i elevations in micro- vs. macro-vascular endothelial cells. DAG 
remains tethered to the plasma membrane to directly gate two members of the non-selective cation 
family of canonical TRP channels (TRPC), namely TRPC3 and TRPC6, in human microvascular 
endothelial cells (Moccia et al., 2012; Fiorio Pla and Gkika, 2013; Pupo et al., 2011). TRPC3 and 
TRPC6, in turn, mediate a monotonic increase in intracellular Ca2+ levels which do not require 
further Ca2+ release from the endogenous Ca2+ pool. Conversely, in human umbilical vein 
endothelial cells (HUVECs), InsP3 rapidly diffuses across peripheral cytosol to InsP3 receptors 
(InsP3Rs), which are embedded in the membrane enveloping the endoplasmic reticulum (ER), the 
most abundant endothelial Ca2+ reservoir. InsP3Rs function as Ca2+-permeable channels to release 
lumenally stored Ca2+ upon InsP3 binding, thereby causing a rapid increase in [Ca2+]i. The 
consequent emptying of the ER Ca2+ pool signals the opening of store-operated Ca2+ channels 
(SOCs) in the plasma membrane (Moccia et al., 2012; Moccia, Dragoni et al., 2012). The ensuing 
influx of Ca2+ shapes a plateau phase of intermediate magnitude between pre-stimulation Ca2+ 
levels and the InsP3-dependent initial peak that persists as long as VEGF is presented to the cells 
(Abdullaev et al., 2008; Li et al., 2011). Store-operated Ca2+ entry (SOCE) is a ubiquitous 
mechanism that, in addition to replenishing the endogenous Ca2+ pool, delivers the bolus of Ca2+ 
necessary for the recruitment of a plethora of endothelial Ca2+-sensitive decoders, including eNOS, 
nuclear factor of activated T-cells (NFAT), nuclear factor kappa-light-chain-enhancer of activated 
B-cells (NF-κB), activating protein-1 (AP-1), calpain and myosin light chain kinase (MLCK) 
(Mocciaet al., 2012; Moccia, Dragoni et al., 2012; Holmes et al., 2010; Rinneet al., 2009; Berra-
Romani et al., 2013). Briefly, endothelial SOCE may be initiated by Stromal Interaction Molecule-1 
(Stim1), which senses the drop in ER Ca2+ concentration and rapidly (40-60 sec) oligomerises into 
clustered puncta that approach as close as 20-30 nm to the plasma membrane. Herein, Stim1 binds 
to and gates two structurally different types of endothelial SOCs, depending both on the species and 
the vascular bed. Accordingly, Stim1 exclusively establishes a physical interaction with Orai1, i.e. 
the pore-forming subunit of the Ca2+ release-activated Ca2+ (CRAC) channel, in HUVECs 
(Abdullaev et al., 2008; Li et al., 2011). Conversely, TRPC1 and TRPC4 provide the core 
components of plasmalemmal SOCs in mouse aorta (Freichel et al., 2001) and rodent pulmonary 
artery (Cioffi et al., 2012). In particular, in rat pulmonary artery endothelial cells (PAECs), the fall 
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in intralumenal Ca2+ induces Stim1 to relocate into sub-plasmalemmal puncta in a TRPC4-
dependent manner, thereby promoting the association of TRPC4 with TRPC1 (Sundivakkam et al., 
2012). This mechanism recognizes a privileged role for Orai1, which constitutively interacts with 
TRPC4 in un-stimulated cells, increases the probability of TRPC1/TRPC4 activation by Ca2+ 
depletion and confers Ca2+-selectivity to the complex (Cioffi et al., 2012). 
VEGF is not the only growth factor to utilize Ca2+ signals to exert a mitogenic effect on mature 
endothelial cells. Insulin-like growth factor-1 (IGF-1) and bFGF trigger a massive entry of Ca2+ 
from the extracellular milieu in bovine aortic endothelial cells (BAECs), which is required for them 
to proliferate (Munaron and Fiorio Pla, 2000; Antoniotti et al., 2003). Subsequent studies have led 
to the conclusion that arachidonic acid (AA) mediates bFGF-evoked Ca2+ inflow by activating TRP 
Vanilloid 4 (TRPV4) (A Fiorio Pla et al., 2012). TRPV4-mediated Ca2+ influx might promote 
endothelial proliferation and vascular remodelling by enlisting a variety of Ca2+-dependent 
transcription factors, such as NFAT, myocyte enhancer factor 2C (MEF2C), Kv channel interacting 
protein 3, calsenilin (KCNIP3/CSEN/DREAM), and cytoplasmic, calcineurin-dependent 1 
(NFATc1) (Troidl et al., 2009; Troidl et al., 2010). EGF, in turn, elicits cytosolic and nuclear Ca2+ 
oscillations in rat microvascular endothelial cells (Moccia et al., 2003), while platelet-derived 
growth factor (PDGF) evokes irregular fluctuations of [Ca2+]i in porcine aortic endothelial cells 
(Ridefelt et al., 1995). This spiking response relies on the rhythmic Ca2+ discharge from InsP3Rs 
and is maintained by the Stim1-mediated activation of Orai1 (Chen et al., 2011; Moccia et al., 2003; 
Ridefelt et al., 1995). Unfortunately, the physiological outcome of EGF- and PDFG-induced 
intracellular Ca2+ spikes has not been probed in these studies; however, endothelial cells often use 
the information encoded in the oscillatory pattern to finely tune their Ca2+-sensitive decoders that 
promote their pro-angiogenic behaviour (Pal et al., 2006; Scharbrodt et al., 2009; Berra-Romani et 
al., 2012; De Bock et al., 2011; Zhu et al., 2008). In addition to mitogens, the chemo-attractant 
SDF-1α may induce endothelial migration in vitro and homing of bone marrow-derived HSCs to 
the target vasculature in vivo through an increase in [Ca2+]i (Moccia, Dragoni et al. 2012; Seidel et 
al., 2007). The signalling pathway downstream of its G-protein coupled receptor, CXCR4, is still 
elusive, but it may involve both InsP3-gated Ca2+ release (Moccia et al., 2012) and store-dependent 
Ca2+ inflow (Seidel et al., 2007).  
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Figure 7. The Ca2+-toolkit in mature ECs (Moccia et al., 2012). 
 
VEGF EVOKES PRO-ANGIOGENIC Ca2+ OSCILLATIONS IN NORMAL ECFCs 
Among the different subsets of EPCs utilized to induce the angiogenic switch in solid cancers, we 
focussed on ECFCs, or late outgrowth EPCs, for four main reasons. First, they are the only EPC 
population possessing all the features of a true endothelial progenitor and do display any known 
haematopoietic marker. Second, unlike CFU-ECs and CACs, they are capable of forming capillary-
like structures in vitro, to originate patent vessels and to anastomose with host vasculature in vivo 
(Yoder, 2012; Basile and Yoder, 2014). Third, they home to sites of malignant growth and 
physically engraft within nascent vessels, thereby enhancing tumor size and vascularization 
(Bieback et al., 2013; Smadja et al., 2010). Fourth, they do require VEGF to proliferate, assembly 
into bidimensional tubulary networks, and differentiate into mature endothelial cells (Turtoi et al., 
2012; Song et al., 2013; D. Yu et al., 2014). Our Ca2+ imaging recordings disclosed that 10 ng/ml 
VEGF, which is quite close to the dose (25 ng/ml) employed by Ingram and coworkers to stimulate 
ECFC expansion in the seminal study that led to their identification (Ingram et al., 2004), triggered 
asynchronous oscillations in [Ca2+]i in neighbouring cells from the same coverslip (Dragoni et al., 
2011). There were no two synchronous cells generating coordinated elevations in [Ca2+]i in the 
ECFC monolayer. Such heterogeneity is the hallmark of mitogens-induced Ca2+ fluctuations in 
mature endothelial cells as well as other non-excitable cell types (Moccia et al., 2003; Ridefelt et 
al., 1995; Pal et al., 2006). Statistical analysis revealed the stochastic nature of VEGF-induced 
/TRP
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intracellular Ca2+ oscillations, as the standard deviation (SD) of their period was of the same order 
as the average value (Dragoni et al., 2011; Skupin and Falcke, 2007; Skupin et al., 2008). We have 
discussed elsewhere the molecular underpinnings of the variability in the Ca2+ response to VEGF in 
healthy ECFCs (Moccia, Lodola et al. 2014; Moccia et al. 2012). Briefly, this diversity, that is 
retained by umbilical cord blood-derived ECFCs (Dragoni et al., 2013), may be engendered by at 
least two different sources. First, VEGF binding to VEGFR-2 obeys to a stochastic regime in 
vascular endothelium, which is key to determine the angiogenic phenotype, i.e. proliferative (tip 
cells) vs. migratory (stalk cell), adopted by the target cell (Potente et al., 2011; Mac Gabhan et al., 
2005). Second, it is likely that the molecular nature and the spatial arrangement of Ca2+ release and 
entry sites dictates the timing of spike generation for each single ECFC (Skupin and Falcke, 2007; 
Skupin et al., 2008; Thurley et al., 2012). Normal ECFCs possess all the three known isotypes of 
InsP3Rs, namely InsP3R-1, InsP3R-2, and InsP3R-3, the pattern of expression of their transcripts 
being InsP3R-3>InsP3R-2>InsP3R-1 (Dragoni et al. 2011). Conversely, they are devoid of 
functional ryanodine receptors (Sánchez-Hernández et al., 2010), whose expression and biological 
meaning in mature endothelium have been largely debated (Moccia et al., 2012) . Additionally, 
ECFCs are insensitive to H2S stimulation, which elicits robust Ca2+ signals in normal endothelial 
cells (Pupo et al., 2011; Moccia et al., 2011; Munaron et al., 2013) and mediates VEGF-induced 
Ca2+ entry in breast cancer-derived TEC (Pupo et al., 2011). VEGF-induced Ca2+ oscillations were 
suppressed by U73122, which selectively blocks PLCγ activity, but not by its close inactive 
analogue, U73343; and by 2-aminoethoxydiphenyl borate (2-APB), which selectively abrogates 
Ca2+ release from InsP3Rs under our experimental conditions, i.e. in the absence of Ca2+ in the 
bathing solution (0Ca2+) (Dragoni et al., 2011). The Ca2+ transients developed regardless of the 
presence of extracellular Ca2+, which suggests that they are primarily driven by Ca2+ recycling 
across the ER membrane; however, they persisted only for a short time in Ca2+-free saline and 
resumed only on Ca2+ restitution to the cells (Dragoni et al., 2011). Therefore, InsP3-dependent Ca2+ 
release is sufficient to initiate and support the irregular episodes of intracellular Ca2+ mobilization 
in ECFCs, but Ca2+ entry across the plasma membrane is necessary to maintain the oscillations over 
time. So, which is the membrane pathway conducting extracellular Ca2+ into these endothelial 
precursors? Unlike mature endothelial cells, human circulating ECFCs lack TRPC3 and TRPC6 
(Dragoni et al., 2011; Dragoni et al., 2013), which mediate VEGF-evoked Ca2+ entry in a DAG-
dependent manner. Conversely, they express all the putative components of SOCE, i.e. Stim1-2, 
Orai1-3, TRPC1 and TRPC4 and exhibit a massive Ca2+ influx in response to ER Ca2+ store 
depletion. Therefore, ECFCs rely on a store-dependent mechanism rather than on a DAG-sensitive 
conductance to sustain prolonged intracellular Ca2+ signals. Consistent with this notion, 1-oleoyl-2-
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acetyl-sn-glycerol (OAG), a membrane permeable analogue of DAG, does not evoke any detectable 
Ca2+ inrush (Dragoni et al., 2013). This feature rules out the possibility that TRPC1 forms a second 
messenger-operated channel gated by DAG in human ECFCs, as reported in human prostate cancer 
cells (Sydorenko et al., 2003). Therefore, SOCE provides the molecular gateway for Ca2+ inflow in 
response to agonist stimulation in endothelial precursors (Yu et al., 2010; Sánchez-Hernández et 
al., 2010; Lodola et al., 2012). Parallel work conducted both by us and Prof. Beech’s lab 
demonstrated that SOCE is mediated by Stim1, Orai1 and TPC1 in endothelial committed 
progenitors. RNA interference selectively targeting either Stim1 or Orai1 abolished store-dependent 
Ca2+ influx in these cells (J. Li et al., 2011; Lodola et al., 2012). Likewise, SOCE was abrogated by 
the expression of a dominant negative mutant Orai1 (R91W), whereas InsP3-evoked emptying of 
the ER Ca2+ pool induced eYFP-GFP tagged Stim1 to cluster into peripheral puncta (Li et al., 
2011). Finally, short hairpin RNA-mediated knockdown of TRPC1 dramatically decreased the 
magnitude of store-dependent Ca2+ entry in human ECFCs (Lodola et al., 2012). These molecular 
data are supported by the pharmacological profile of SOCE, that is sensitive to a wide spectrum of 
rather specific inhibitors of both Orai1 and TRPC1 in these cells, including low micromolar doses 
of the trivalent cations La3+ and Gd3+, 2-APB and YM-58483/BTP2 (Moccia, Dragoni et al. 2014; 
Moccia, Dragoni et al. 2012). The question the arises as to whether these two channel proteins 
assembly into a super-molecular ternary complex with Stim1, as illustrated in megakaryocytes (Di 
Buduo et al., 2014) and mouse submandibular gland cells (Ong et al., 2007), of constitute two 
distinct Ca2+-permable routes, each recruited by Stim1 (Moccia, Dragoni et al. 2012). Suppression 
of either Orai1 or TRPC1 expression reduced SOCE amplitude to the same extent (Lodola et al., 
2012), thereby suggesting that both of them contribute to the pore forming channel in human 
ECFCs. The molecular and pharmacological characterisation of the most important Ca2+-permeable 
route in endothelial committed progenitors enabled us to ascertain its participation to VEGF 
signalling. One 1-to-4 Ca2+ transients arose when the cells were challenged with VEGF in the 
presence of BTP2, whose effect on Ca2+ fluctuations thus mimicked the removal of extracellular 
Ca2+ (Dragoni et al., 2011). In addition, VEGF-evoked Ca2+ influx was nearly absent in normal 
ECFCs transfected with a siRNA directed against Stim1 or Orai1 (Li et al., 2011), which is 
consistent for SOCE requirement to maintain the spiking response to VEGF (Dragoni et al., 2011). 
Thus, the molecular machinery that translates the extracellular input carried by VEGF into a 
specific intracellular output, i.e. a defined biological response, involves both InsP3Rs and SOCs in 
normal ECFCs. The well known signalling role served by Orai1 and TRPC1 in mature endothelium 
suggests that SOCE does more than replenishing depleted Ca2+ stores during the oscillatory 
response to VEGF in endothelial precursors.  
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VEGF-elicited Ca2+ oscillations drive proliferation and tube formation in healthy ECFCs. The pro-
angiogenic activity of VEGF disappeared when the cells were pre-treated with BAPTA, a strong 
membrane-permeable Ca2+ buffer, or BTP2 to hinder the ensuing elevation in [Ca2+]i (Dragoni et 
al., 2011). Similarly, siRNA-mediated genetic ablation of Orai1 prevented ECFC tubulogenesis (J. 
Li et al., 2011). Therefore, VEGF utilizes intracellular Ca2+ signals to promote endothelial 
proliferation and remodelling not only in mature endothelial cells, but also in their progenitors. The 
Ca2+-sensitive decoder translating the irregular fluctuations in [Ca2+]i into a biologically meaningful 
message is represented by NF-κB. The NF-κB signalling system includes about a dozen different 
dimmers comprising five homologous subunits, i.e. p50, p52, c-Rel, RelA/p65 and RelB (Hoffmann 
et al.,2006). The cytosolic-nuclear localization of NF-κB is intricately tuned and regulates several 
key steps of the angiogenic process, including endothelial cell proliferation, survival motility, 
substrate adhesion, interaction with the extracellular matrix and capillary morphogenesis (Minami 
and Aird, 2005). The heterodimer formed by p65 with p50 or p52 is sequestered in the cytosol by 
the association with IkB, an inhibitory protein which masks the nuclear localisation sequence of the 
complex. A burst of intracellular Ca2+ oscillations recruits Ca2+/calmodulin (CaM)-dependent 
protein kinase IV (CaMKIV) to activate the enzyme I κ B kinase (IKK). IKK, in turn, 
hyperphosphorylates IκB on two specific NH2-terminal serines and target the inhibitory protein to 
site-specific ubiquitination and eventual degradation by the proteasome (Mellström et al., 2008). As 
a consequence, NF-κB dimers are released from inhibition and freed into the nucleus, where they 
turn on the transcriptional programme controlling EPC fate (Su et al., 2013; Li et al., 2012). 
Consistent with this model, the pharmacological extinction of VEGF-induced Ca2+ oscillations with 
either BAPTA or BTP2 hindered VEGF-induced IkB phosphorylation in normal ECFCs; as 
expected, the same effect was exerted by thymoquinone, which selectively interfered with NF-κB 
activation (Dragoni et al., 2011). The final observation that thymoquinone abrogated ECFC 
expansion and tubule formation confirmed that NF-κB served as the Ca2+-dependent decoder of 
VEGF-evoked Ca2+ transients (Dragoni et al., 2011). It has long been thought that NF-κB 
stimulation by a spiking signal in endothelial cells is controlled by the interspike interval (ISI). The 
transcriptional activity of endothelial NF-κB reaches its peak within a frequency range of Ca2+ 
spikes ranging from 0-5.2 mHz to 1.7-11.7 mHz (Smedler and Uhlén, 2014). This property does not 
fully apply to VEGF-challenged ECFCs, which generate irregular Ca2+ transients. However, resting 
cells do not exhibit any detectable elevation in [Ca2+]i, so that the informative content of the 
irregular Ca2+ spikes is obvious as compared to silent ECFCs. Recent mathematical computation 
has unveiled that any deviation from the pattern of Ca2+ spikes in un-stimulated cells conveys a 
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robust (i.e. high signal-to-noise ratio) message to their downstream effectors, thereby triggering a 
biological response (Skupin and Falcke, 2007; Thurley et al., 2012). The same group has further 
demonstrated that the cell-to-cell heterogeneity in the Ca2+ train notwithstanding, stochastic 
oscillations exhibit a linear correlation between the standard deviation of ISI and the average period 
of the spikes. It turns out that, under different experimental conditions (e.g. agonist dose, extent of 
cytosolic Ca2+ buffering, cell type), frequency encoding is realized by moving up and down this 
relation (Skupin et al., 2010). Interestingly, when ECFCs are exposed to 10 ng/ml VEGF, the 
interval between two consecutive Ca2+ transients in most cells ranges between 200 sec and 800 sec 
(Dragoni et al., 2011), which is adequate to induce the nuclear translocation of NF-κB (Smedler and 
Uhlén, 2014). Conversely, when VEGF concentration is raised to 50 ng/ml, the ISI may be 
lengthened to 1500 sec, which is less efficient to stimulate NF-κB. An alternative, albeit not 
mutually exclusive, mechanism whereby irregular Ca2+ fluctuations are decoded involves the spatial 
distribution of the underlying Ca2+ toolkit. Local Ca2+ microdomains may be generated around the 
cytosolic mouth of Ca2+-permeable channels to convey information to specific Ca2+-sensitive 
decoders located in their immediates surroundings. The seminal example has been provided by 
Parekh’s group (Parekh, 2009), who demonstrated that leukotriene C4-induced Ca2+ oscillations 
induced gene expression and mast cell activation only when they were patterned by Orai1, while 
were inefficient if exclusively contributed by InsP3Rs. The randomness of VEGF-induced Ca2+ 
spikes in ECFCs might be translated into a biologically meaningful code by the selective activation 
of either InsP3Rs or store-dependent channels (e.g. Orai1 and TRPC1) or both. These preliminary 
studies paved the way for the subsequent examination of the Ca2+ response to VEGF in tumor 
ECFCs. Once established that VEGFR-2 is capable of delivering a pro-angiogenic Ca2+ signal to 
their normal counterparts, we sough to elucidate whether this pathway was altered in cancer 
patients-derived cells and whether it could serve as an alternative target in oncology. 
 
RATIONALE FOR STUDYING THE Ca2+ MACHINERY IN ECFCs DERIVED FROM 
RCC PATIENTS 
It has long been established that neoplastic transformation is accompanied by a remodelling of the 
Ca2+ toolkit, which may not be key to malignant initiation, but may contribute to establish some of 
the ten hallmarks of cancer (Monteith et al., 2007; Prevarskayaet al., 2011; Roderick and Cook, 
2008), including enhanced proliferation, survival, angiogenesis and invasion. The derangement of 
the Ca2+ machinery is not limited to neoplastic cells, but may also be extended to tumor 
microenvironment (Nielsen et al., 2014). Accordingly, TECs harvested from breast carcinoma up-
regulate TRPV4, which governs the rearrangement of actin cytoskeleton driving endothelial cell 
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migration during the angiogenic switch (A Fiorio Pla et al., 2012). Moreover, normal HMECs may 
be reprogrammed by adriamycin-resistant human breast cancer cells (MCF-7/ADM) to express 
TRPC5, which is otherwise absent in normal cells (Dong et al., 2014). Therefore, we wondered 
whether tumor ECFCs, which do not belong to the neoplastic clone and are isolated from the 
mononuclear fraction of peripheral blood (Basile and Yoder, 2014), could somehow be influenced 
by the malignant conditions of the donor. The urgency of this study was further prompted by the 
simultaneous investigation of Ca2+ dynamics in ECFCs isolated from other two sources, i.e. 
umbilical cord blood (UCB) and peripheral blood of individuals affected by primary myelofibrosis 
(PMF). We found that the Ca2+ toolkit may be assembled according to rather different modes in 
endothelial precursors depending on the superimposed patho-physiological background. For 
instance, TRPC3, which is absent in circulating ECFCs, appears on the plasma membrane of their 
UCB counterparts to mediate the influx of Ca2+ that triggers the oscillatory response to VEGF 
(Dragoni et al., 2011; Sánchez-Hernández et al., 2010). A more dramatic dysregulation of the Ca2+ 
machinery occurs in ECFCs derived from PMF patients (PMF-ECFCs), who suffer from fibrotic 
bone marrow, splenomegaly, cytopenias, and multiple disease-related symptoms that reduce quality 
and length of life (Barosi et al., 2012). PMF-ECFCs display a higher ER Ca2+ load, which is 
associated to the over-expression of all InsP3R transcripts as well as of Stim1, Orai1, Orai3, TRPC1 
and TRPC4 proteins (Dragoni et al., 2014). It is, therefore, not surprising that SOCE magnitude is 
significantly enhanced, albeit two separate routes may be discriminated based on their 
pharmacological profile: one stimulated by passive store depletion and Gd3+-resistant, the other one 
recruited by the InsP3-dependent Ca2+ store and Gd3+-sensitive (Dragoni et al., 2014). A remarkable 
feature of these cells, that distinguishes them from both peripheral blood- and UCB-derived ECFCs 
(Dragoni et al., 2013; Sánchez-Hernández et al., 2010), is their relative insensitivity to SOCE 
inhibitors. BTP-2 and La3+ barely affected the proliferation rate, while Gd3+ was inefficient 
(Dragoni et al., 2014). This finding suggested that VEGF may exploit signalling pathways other 
than an increase in [Ca2+]i to control ECFC replication in a pathological context; in addition, it 
reawakened the interest towards the earlier notion that proliferative diseases, such as cancer, may 
turn off the requirement for extracellular Ca2+ to drive cell cycle progression into mitosis (Jaffe, 
2005). This concept does not rule out the contribution of Ca2+-permeable channels, which may 
serve as scaffold proteins to orchestrate the proliferative process independently on their Ca2+-
conducting properties, as recently shown for Orai1 and Orai3 in several cell lines (Borowiec et al., 
2014). However, it might have profound therapeutic implications as the in situ disruption of their 
encoding genes is far less feasible than pharmacological abrogation of Ca2+ fluxes. Therefore, we 
felt the urgency to examine the remodelling, if any, of Ca2+ signalling in ECFCs isolated from 
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metastatic RCC patients (RCC-ECFCs). First, RCC is the most common type of kidney cancer in 
the adults, and several strong evidences hint at EPC participation to the angiogenic switch in 
primary tumor (Moccia et al., 2014; Hill, 2010; Bhatt et al., 2011; Yang et al., 2012; Akino et al., 
2009). Second, metastatic RCC is the only human cancer where the standard care for treatment is 
represented by anti-angiogenic drugs, such as bevacizumab, sunitinib, and sorafenib (F Moccia et 
al., 2014; Escudier et al., 2012). As described in a previous paragraph, however, clinical practice 
revealed that a fraction of the patients is intrinsically refractory towards this treatment, while those 
who undergo an initial remission display a later tumor relapse and ultimately die (Moccia et al., 
2014; Escudier et al., 2012). However, TECs cultured from human RCC do respond to VEGF 
stimulation, which renders them sensitive to bevacizumab, sunitinib and sorafenib (Bussolati et al., 
2003). It turns out that an additional component of tumor vasculature must be refractory to this 
growth factor (F Moccia et al., 2014). All the studies described above concurred to demonstrate that 
EPCs require a functional VEGFR-2 to sustain the malignant transformation, but they drew this 
conclusion by exploiting normal, rather than tumor, cells. Third, RCC has recently been associated 
to an important derangement of Ca2+ machinery, Orai1 and TRPC6 expression being enhanced in 
primary tumor samples as compared to normal renal tissues (J. Song et al., 2013; Kim et al., 2014). 
Conversely, TRPC4 is down-regulated in two different human kidney carcinoma cell lines as 
related to normal human epithelial renal cells (Veliceasa et al., 2007). These alterations may play a 
central role in the neoplastic transformation of normal kidney. While TRPC6 up-regulation favours 
the transition through G2/M phase (J. Song et al., 2013), and Orai1 regulates RCC cell proliferation 
and migration (Kim et al., 2014), the loss of TRPC4 leads to a diminished secretion of the 
endogenous inhibitor thrombospondin-1, thereby promoting the angiogenic switch (Veliceasa et al., 
2007). Thus, understanding whether RCC-ECFCs develop Ca2+-handling abnormalities might 
permit the accomplishment of two goals. It could unveil alterations in the pro-angiogenic signalling 
pathways initiated by VEGF, thereby providing a solid cellular and molecular rationale for the 
failure of anti-VEGF therapies; and, at the same time, it could highlight unforeseen targets, i.e. 
Ca2+-permeable ion channels and/or Ca2+ transporters, to devise alternative treatments. 
 
THE Ca2+ SIGNALLING TOOLKIT IS REARRANGED IN ECFCs ISOLATED FROM 
PATIENTS SUFFERING FROM RCC 
Based on the rationale above, we analyzed the Ca2+ machinery in ECFCs isolated from naïve RCC 
patients (RCC-ECFCs), before they underwent to anti-angiogenic treatments. We found that the ER 
Ca2+ content is dramatically lower in RCC-derived cells as compared to control cells, albeit the 
resting Ca2+ levels are not different (Lodola et al., 2012). In addition, RCC-ECFCs lack InsP3R1 
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transcripts, InsP3R2 and InsP3R3 being less abundant than in normal ECFCs. These cells are, 
therefore, less prone to release Ca2+ from intracellular stores. This feature gains particular relevance 
when recalling that a decreased ER Ca2+ load may protect tumor cells from mitochondrial Ca2+ 
overload, thereby preventing the permeabilization of the outer mitochondrial membrane and 
inhibiting the release of apoptogenic factors (Prevarskaya et al., 2004; Prevarskaya et al., 2014). In 
this view, TECs isolated from several types of solid tumors, including RCC and breast cancer, are 
extremely resistant to apoptosis induced by serum starvation and by vincristine, a well known 
chemotherapeutic (Bussolati et al., 2010). Since renal TECs include bone marrow-derived cells, it 
has been speculated that this pro-survival phenotype is, at least partially, linked to the reduction in 
the intracellular Ca2+ reservoir detected in EPCs (Moccia et al. 2014; Moccia and Poletto 2014). 
This therapeutically relevant feature, however, remains to be experimentally probed. Moreover, 
these experiments were performed by measuring the amplitude of the peak fluorescence emitted by 
the Ca2+-fluorophore Fura-2/AM when the cells were bathed in the absence of extracellular Ca2+ 
and challenged with cyclopiazonic acid (CPA). CPA is a selective inhibitor of SERCA activity that 
blocks Ca2+ re-uptake into the ER and unmasks an endogenous Ca2+ leak across ER membrane 
(Dragoni, Laforenza et al., 2014; Lodola et al., 2012). Consequently, CPA induces an increase in 
[Ca2+]i that is supposed to reflect [Ca2+]ER (Bergner et al., 2009; Lodola et al., 2012). Nevertheless, 
CPA-induced elevation in [Ca2+]i might not provide the most accurate estimation of ER Ca2+ 
content as this organelle is rather uneven and CPA-sensitive pumps might reside in leakage 
channels-free sub-regions. Furthermore, the lower increase in [Ca2+]i elicited by CPA could depend 
on the activation of ER-independent sequestration mechanisms, such as mitochondria, as discussed 
in (Vanden Abeele et al., 2002) and (Vanoverberghe et al., 2004). Thus, direct measurement of ER 
Ca2+ levels is mandatory to confirm that RCC-ECFCs undergo a drop in their intraluminal Ca2+ 
concentration. Conversely, SOCE is up-regulated in RCC-ECFCs due to the over-expression of 
Stim1, Orai1, and TRPC1 mRNAs and proteins, and has an important role in their angiogenic 
behaviour (Lodola et al., 2012). Accordingly, both cell proliferation and tubulogenesis are inhibited 
by BTP-2, low micromolar doses of La3+ and the anti-angiogenic agent CAI (Lodola et al., 2012). 
The blocking effect exerted by CAI is particularly intriguing, as it has been employed as cytostatic 
agent of the disease in Phase II clinical trials of subjects with advances RCC and refractory to 
immunotherapy (Dutcher et al., 2005; Stadler et al., 2005). Conversely, RCC are insensitive to 
OAG (unpublished observations from our group) and do not present the transcripts encoding for 
DAG-sensitive channels, i.e. TRPC3 and TRPC6 (Lodola et al., 2012). Another puzzling feature of 
Ca2+ signalling in RCC-ECFCs is represented by their lack of responsiveness to VEGF, despite the 
fact that VEGFR-2 expression is unaltered in these cells (Lodola et al., 2012). Accordingly, RCC-
ECFCs do not manifest any detectable elevation in [Ca2+]i when exposed to VEGF. It is conceivable 
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that either the decrease in ER Ca2+ content and/or the down-regulation of InsP3Rs render these cells 
less prone to release Ca2+ in response to VEGF. This result has at a least two patho-physiological 
implications. First, the physiological activator of SOCE must be a growth factor other than VEGF, 
albeit we cannot rule out the possibility that a VEGF-induced sub-membranal Ca2+ elevation occurs 
and is missed by our Ca2+ imaging system. Second, all VEGF targeting therapies might fail in 
interfering with ECFC mobilization from bone marrow in RCC patients. Indeed, if VEGFR-2 is 
expressed by RCC-ECFCs, but does not activate any pro-angiogenic Ca2+ signal, either VEGF 
monoclonal antibodies (bevacizumab) or TKR inhibitors (sunitinib and sorafenib) will not have any 
impact on SOCE activation and recruitment of its downstream Ca2+-sensitive machinery. However, 
VEGF could exert its pro-angiogenic effect by inducing the nuclear translocation of NF-κB through 
alternative pathways NF-κB transcriptional activity may, however, be recruited by signalling 
pathways other than Ca2+, such as protein kinase C (PKC), mitogen-activated protein kinases 
(MAPK)/ extracellular signal-regulated kinases (ERK), phosphatidylinositol 3-kinase 
(PI3K)/protein kinase B (Akt), glycogensynthase kinase-3β (GSK3β) and casein kinase II (CKII). 
Thus, further investigation is required to assess whether VEGF does stimulate RCC-ECFCs. 
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AIM OF THE WORK 
 
The aim of this project is to initially carry out the phenotypical and functional characterization of 
ECFCs isolated from healthy subjects and from patients affected by RCC. Although EPCs have 
been extensively studied in last few years, they are always subjects of debate about their 
phenotypical identification and their role in physiological and pathological processes. We focus on 
the differences, if any, in frequency, proliferation rate, in vitro tubulogenesis and apoptosis between 
healthy and tumor-derived ECFCs. Next, we assess whether and how VEGF-induced Ca2+-
dependent protein expression in altered in RCC-ECFCs, which fail to generate pro-angiogenic Ca2+ 
oscillations in response to this growth factor. Since our data point at a decrease in ER Ca2+ 
concentration as a major responsible for the lower sensitivity of RCC-ECFCs to pro-apoptotic 
insults and to VEGF stimulation, we finally focus on the molecular mechanisms responsible for the 
drop in ER Ca2+ levels.  
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MATHERIALS AND METHODS 
 
ECFC ISOLATION AND CULTIVATION 
PB samples (about 40 mL) were obtained from healthy human volunteers and from RCC patients 
from Structure of Medical Oncology, Policlinico San Matteo Foundation, Pavia. The demographic 
characteristics of patients and healthy donors are summarized in Table 1. The Institutional Review 
Board at “Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation” in 
Pavia approved all protocols and an informed consent was signed by patients and HDs. The study 
was conducted according to the principles of the Declaration of Helsinki.  
 
 
 
Table 1. Demographic characteristics of patients and healthy donors (HD) involved in the 
study (N.A.: not applicable). 
 
 
To isolate ECFCs, MNCs were separated from PB by density gradient centrifugation on 
lymphocyte separation medium for 30 min at 400g and washed twice in EBM-2 with 2% FCS. 
After counting in a Burker chamber, a median of 36x106 MNCs (range 18-66) were plated on 30 
mm collagen-coated culture dishes (Becton Dickinson (BD) Biosciences, Franklin Lakes, New 
Jersey) in the presence of the endothelial cell growth medium EGM-2 MV Bullet Kit (Lonza, Basel 
Switzerland) containing endothelial basal medium (EBM-2), 5% foetal bovine serum, recombinant 
human (rh) EGF, rhVEGF, rhFGF-B, rhIGF-1, ascorbic acid and heparin, and maintained at 37°C 
in 5% CO2 and humidified atmosphere. Discard of non-adherent cells was performed after 2 days; 
thereafter medium was changed three times a week. The outgrowth of ECFCs from adherent MNCs 
was characterized by the formation of a cluster of cobblestone-appearing cells after between 8 and 
21 days of culture (Sánchez-Hernández et al., 2010). Once colonies were detached by 
trypsinization (trypsine/EDTA, Sigma Aldrich, St Louis, Missouri), monolayers of endothelial cells 
were obtained in the following passages.  
 
IMMUNOPHENOTYPICAL ANALYSIS 
Cells were trypsinized, recovered and incubated with the primary or isotopic control antibody for 
twenty minutes at 4°C. Cells were then washed and analysed by a fluorescence-activated cell sorter 
 Number Age [range] Male/Famele Chemotherapy Metastasis 
Patients 27 50 [38-67] 15-12 NO NO 
HD 34 39 [27-54] 19-15 N.A. N.A. 
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(FACS; BD Biosciences). The following antibodies were used (all provided by BD Bioscience 
unless otherwise indicated): FITC-conjugated anti-CD34, FITC-conjugated anti-CD31, PE-
conjugated anti-CD45; FITC-conjugated anti-CD105; FITC-conjugated anti-CD144; PE-conjugated 
anti-CD146; PerCP-conjugated anti VEGFR-2, and FITC-conjugated anti-CD133. All the 
antibodies have been obtained from BD Biosciences. Cells (2x105) were acquired by flow 
cytometer (FACSCanto, Becton Dickinson), and analysed by CellQuest software (BD Biosciences). 
 
PROLIFERATION ASSAY 
1,5x104 ECFCs (1st passage) were plated in 5 collagen treated wells (30mm) in EGM-2 medium. 
Cultures were incubated at 37°C (in 5% CO2 and humidified atmosphere). The day after, cells were 
recovered by trypsinization and counted with a Burker chamber. This passage was performed for 
other 3 times in the three following days, about at the same hour, with the remaining cells.  
 
IN VITRO TUBULOGENESIS ASSAY 
In vitro tubulogenesis assay was performed using MatrigelTM (BD Biosciences, Franklin Lakes, 
New Jersey). The composition of the substrate is laminin, collagen IV, entactine and proteoglycan 
isolated from a mouse sarcoma (Engelbreth-Holm-Swarm), a tumor embedded by proteins of 
extracellular matrix. At room temperature, MatrigelTM polymerizes and produces a biologically 
active scaffold which mimics the mammalian cells basal membrane. From 5 to 10x103 ECFCs were 
resuspended in 200 μl EGM-2 and incubated onto a thin layer of MatrigelTM at 37°C in 5% CO2 in 
96 wells plate. Between 4 and 36 hours from the seeding, ECFCs-derived cells form a capillary-like 
tridimensional structure which reproduces the in vivo vessels network and was observed by visual 
observation using an inverted microscope. At least 3 different sets of cultures were performed per 
every experimental point. 
 
APOPTOSIS ASSAY 
For apoptosis investigation, the In Situ Cell Death Detection Kit, AP (Roche, Life Science, Basel, 
Switzerland) which is based on the detection of single- and double-stranded DNA breaks that occur 
at the early stages of apoptosis, was used. RCC-ECFCs and N-ECFCs were plated in Nunc™ Lab-
Tek™ II Chamber Slide™ System (Thermo Scientific, Waltham, Massachussets), at a density of 
3x103 cells per well, in 300 μl EGM-2 medium. The day after, cells were treated with the apoptosis 
inducers 1 μM thapsigargin (Sigma Aldrich, St. Louis, Missouri) or 5 μg/ml rapamycin (Sigma 
Aldrich, St. Louis, Missouri). After 24 and 48 hours of treatment, the cells were fixed by 
paraformaldehyde (4%) for 1 hour at room temperature and permeabilized (0.1% Triton X-100, 
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0.1% sodium citrate) for 2 minutes on ice. Controls experiments were conducted with cells from the 
same batch, cultured in EGM-2 only. Subsequently, the cells were incubated with the TUNEL 
reaction mixture that contains deoxynucleotidyl-transferase (TdT) and fluorescein dUTP.  
 
Figure 8. Tunel assay (AP: alkaline phosphatase). 
 
During this incubation period, TdT catalyzes the addition of fluorescein-dUTP at free 3'-OH groups 
in single- and double-stranded DNA. After washing, the label incorporated at the damaged sites of 
the DNA is marked by an anti-fluorescein antibody conjugated with the reporter enzyme alkaline 
phosphatase (AP). After washing to remove unbound enzyme conjugate, samples can be analysed in 
a drop of PBS under a fluorescent microscope. Otherwise, the cells could be incubated with 
converter-AP provided by the kit and then treated with Fast Red (Roche), the AP substrate which 
precipitates when interacts with AP and produces a colorimetric reaction which can be analysed 
under optical microscope. ECFCs with red nuclei will be apoptotic cells. 
 
IMMUNOCYTOCHEMISTRY 
Twenty-four hours before treatment with VEGF and the specific Ca2+ inhibitors, 6x104 RCC-
ECFCs and N-ECFCs were plated onto 13 mm coverslips in 24-well plates. The cells were treated 
as described in the previous paragraph. ECFCs-derived cells were fixed in 4% formaldehyde in PBS 
for 15 minutes at room temperature, permeabilized for 7 min in PBS with 0.1% Triton X-100 and 
blocked for 30 min in 2% gelatine. Then, primary (incubated for 1 hour at 37°C) and secondary 
(incubated for 1 hour at room temperature) antibodies were applied in PBS with 2% gelatin. The 
primary anti-p65 (NF-kB subunit) antibody specific for immunocytochemistry (Santa Cruz) was 
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used at 1:50 dilution, whereas AlexaFluor 488 secondary antibody from Life Sciences (Milan, Italy) 
was used at 1:200. After washing (3 times for 5 minutes each), nuclei were stained with 40,6-
diamidino-2-phenylindole dihy-drochloride (DAPI) for 15 minutes at RT. Fluorescence images 
were acquired using a Leica epifluorescent microscope equipped with S Fluor X40/1.3 objective 
using MetaMorph software. 
 
TREATMENT WITH VEGF AND INHIBITORS OF Ca2+ SIGNALLING 
N-ECFCs and RCC-ECFCs were plated in 25 cm2 flasks or in 30 mm wells depending on the cell 
number required for the planned experiments. When cells reached about 90% of confluence in 
EGM2, the growth medium was removed and cells were left for 6 hours in a medium without serum 
and without growth factors (EBM2, Lonza, Basel Switzerland) at 37°C in 5% CO2 and humidified 
atmosphere. Then, VEGF (Promega, Milano, Italy) at 10 ng/ml was added to the medium. For qRT-
PCR analysis of VEGF-induced transcripts, cells were challenged with VEGF for 2, 4, and 6 hours. 
For western blot analysis of VEGF-induced protein expression, the cells were stimulated with 
VEGF for 4 hours. When the effect of specific Ca2+ inhibitors (BTP-2, BAPTA and thymoquinone) 
had to be tested, after the initial 6 hours of washing in EBM2, cells were further treated for 30 
minutes with 20 μM BTP-2 (Calbiochem, La Jolla, Canada), 30 μM BAPTA (Sigma Chemical Co., 
St. Louis, Missouri) and 25 μM thymoquinone (Sigma Chemical Co.). Thereafter, VEGF was added 
and tested at the conditions described above. 
 
RNA ISOLATION AND REAL TIME RT-PCR (qRT-PCR) 
N-ECFCs and RCC-ECFCs cells were challenged with VEGF for 2, 4, and 6 hours. After this 
treatment, cells were detached from 30 mm wells by enzymatic reaction of 200 μl of QIAzol Lysis 
Reagent (QIAGEN, Duesseldorf, Germany). Total RNA was extracted from cells using the QIAzol 
Lysis Reagent (QIAGEN) and miRNeasy Mini Kit (QIAGEN). Single cDNA was synthesized from 
RNA (1 μg) using oligo(dT), random hexamers, and M-MLV Reverse Transcriptase in iScript 
cDNA Syntesis Kit (BIO-RAD, Hercules, Canada). Reverse transcription was always performed in 
the presence or absence (negative control) of the reverse transcriptase enzyme. qRT-PCR was 
performed in triplicate using 1 μg cDNA and TaqMan Assay for gene expression for Real-Time 
PCR (Applied Biosystem|Life Technologies, Waltham, Massachusetts). The genes that were 
analyzed and the corresponding primers are listed in Table 2. 
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Gene Primers sequences Size (bp) Accession number 
BCL2 Hs00608023_m1 TaqMan gene expression Assay 81 NM_000633.2 
MMP9 Hs00234579_m1 TaqMan gene expression Assay 54 NM_004994.2 
ICAM1 Hs00164932_m1 TaqMan gene expression Assay 87 NM_000201.2 
E-SELE Hs00950401_m1 TaqMan gene expression Assay 104 NM_000450.2 
VCAM1 Hs01003372_m1 TaqMan gene expression Assay 62 NM_080682.2 
CCND1 Hs00765553_m1 TaqMan gene expression Assay 57 NM_053056.2 
MYC Hs00153408_m1 TaqMan gene expression Assay 107 NM_002467.4 
SERCA2b 
Forward 5’: AATGTGTAACGCCCTCAACA 
Reverse 5’: GCAGGCTGCACACACTCTT 
282 NM_170665.3 
SERCA3 
Forward 5’: GTGGACCAGTCCATCCTGAC 
Reverse 5’: GCTTTGCCCGATGTGATATT 
134 NM_005173.3 
PMCA1a 
Forward 5’: CCAAACACAGATGGATGTAGTGA 
Reverse 5’: GAAAACACTACATGTGTAGGGGTAGA 
135 NM_001001323.1 
PMCA1b 
Forward 5’: CCAAACACAGATTCGAGTGG 
Reverse 5’: AAGGGGGATATGAGGCTCTG 
142 NM_001682.2 
PMCA4a 
Forward 5’: ACCGTATCCAGACTCAGATCG 
Reverse 5’: TGTTGACCCATGTTCTGTCG 
91 NM_001001396.2 
PMCA4b 
Forward 5’: TCCAGACTCAGATCAAAGTGG 
Reverse 5’: GCTGTGGACTTTTGGTT 
89 NM_001684.4 
NCX1.3 
Forward 5’: GTGCAGTTTCTCCCTTGTGC 
Reverse 5’: TTGTCATCATATTCGTCTGTTATTG 
90 NM_001112802.1 
NCX1.7 
Forward 5’: GTGCAGTTTCTCCCTTGTGC 
Reverse 5’: GCATGAACCTTCCTGAAGACA 
102 NM_001112801.1 
YWHAZ 
Forward 5’: ACTTTTGGTACATTGTGGCTTCAA 
Reverse 5’: CCGCCAGGACAAACCAGTAT 
94 NM_003406.3 
GAPDH 
Forward 5’: CGGATTTGGTCGTATTGG 
Reverse 5’: GGTGGAATCATATTGGAACA 
130 NM_002046.3 
Table 2. Primer sequences/ID TaqMan Gene expression assay used for real-time reverse 
transcription-polymerase chain reaction (bp: base pair).  
 
Sso Advanced Universal Probes Supermix and Sso Fast EvaGreen Supermix (both from BIO-RAD) 
were used according to the manufacturer instructions, and qRT-PCR performed using CFX 96 Real-
Time system, C1000 Thermal Cycler (BIO-RAD). The conditions of the reaction were: initial 
polymerase activation and DNA denaturation at 95°C for 30 seconds; 40 cycles of denaturation at 
95°C for 5 seconds; annealing and extension at 60°C for 5 seconds. The qRT-PCR reactions were 
normalized using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and tyrosine 3-
 50 
monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) as housekeeping 
genes. Melting curves were generated to detect the melting temperatures of specific products 
immediately after the PCR run. The triplicate threshold cycles (Ct) values for each sample were 
averaged resulting in mean Ct values for both the gene of interest and the housekeeping genes. 
Relative mRNA levels were determined by comparative quantitation and the results expressed as 
fold change by CFX manager software 3.0 (BIO-RAD).  
 
CELL LYSIS, PROTEINS EXTRACTION AND IMMUNOBLOTTING 
Protein expression was tested in N-ECFCs and RCC-ECFCs stimulated with VEGF for 4 hours. 
When the effect of BTP-2, BAPTA and thymoquinone had to be tested, cells were further treated 
for 30 minutes with the inhibitors Thereafter, VEGF was added and cells stimulated for 4 hours.  
For protein extraction, radio-immuno precipitation assay (RIPA) buffer was previously prepared 
with the following composition: NaCl 150 mM, 1% triton X-100, 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulfate (SDS), Tris(hydroxymethyl)amino-methane 50mM pH 8.0. All the reagents 
were purchased from Sigma Aldrich. Lysis buffer was prepared with 10 ml of RIPA buffer and 1 
tablet of protease inhibitor cocktail, cOmplete Mini (Roche Life Science, Basel, Switzerland). Each 
step of this protocol was performed on ice. N-ECFCs and RCC-ECFCs were harvested from 25 cm2 
culture flasks and washed twice with cold PBS 1X. 50 μl of lysis buffer was added to each flask and 
adherent cells were scraped by a plastic rubber policeman. Cell suspension was then transferred into 
a microcentrifuge tube, maintained in agitation for 30 minutes at 4° C and then sonicated on ice for 
3 minutes with Sonorex RK100 (Bandelin, Berlin, Germany). Cell lysates were centrifuged at 
14000g for 15 minutes at 4° C, and the supernatant containing the ECFCs total proteins 
homogenized. Protein contents from each sample was determined by the Bradford’s method with 
DC Protein Assay reagent Package (BIO-RAD) using bovine serum albumin (BSA) as standard. 
The homogenates were solubilized in Laemmli buffer (Sánchez-Hernández et al., 2010) and 20 μg 
proteins were separated on 4-15% polyacrylamide mini protean Tris/Glycine/SDS (TGX) precast 
gel for electrophoresis (BIO-RAD) at a fixed voltage of 180V for 45 minutes. The proteins were 
then transferred to the Trans Blot turbo mini PVDF Transfer Membranes (BIO-RAD) by Trans Blot 
Turbo transfer system (BIO-RAD) using pre-set programs from the machine. After 1 hour blocking 
with Tris buffered saline (TBS) containing 7% powder milk (Sigma Aldrich) and 0.1% Tween 
(blocking solution), the membranes were incubated over night at room temperature with the affinity 
purified antibodies listed in Table 3, diluted in TBS and 0.1% Tween containing 1% BSA. Control  
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experiment were performed using an anti-tubulin antibody. 
 
Table 3. Primary antibodies used for the proteins of interest, source, approximative molecular 
weight (MW) and respective diluitions. 
 
 
The membranes were washed and incubated for 1 h with anti-mouse and anti-rabbit IgG 
peroxidase-conjugated secondary antibodies produced in goat (1:50000 in blocking solution) 
(Sigma Aldrich). The bands were detected with clarity western ECL substrate (BIO-RAD). 
Precision Plus Protein™ WesternC™ Standard (BIO-RAD) was used to estimate the molecular 
weights. The Precision Plus Protein™ WesternC™ Standard was used to accurately estimate the 
molecular weight and as a positive control for the immunoblot. Blots were developed in a dark 
room through the exposure of the photographic film Hyperfilm ECL (GE Healthcare Life Sciences, 
Milano, Italy) to ECL treated membranes. Bands were detected with the development in 
Canestream Kodak processing chemicals for autoradiography films, developer solution and 
Canestream Kodak processing chemicals for autoradiography films, fixer solution (Sigma Aldrich). 
Densitometric analysis of the bands was performed by Image-j computer program and the results 
were expressed as a percentage of the protein/tubulin densitometric ratio. 
 
Ca2+ MEASUREMENTS USING LENTIVIRAL AEQUORIN-BASED PROBES 
ER and mitochondrial Ca2+ levels in the lumen of the endoplasmic reticulum (ER) were monitored 
using luminescent Ca2+ sensor aequorin (AEQ). We opted for use of lentiviral AEQ vectors as 
lentiviral transduction assures robust expression of the probe in ECFCs (Lodola et al., 2012). 
Generation of lentiviral vector pLV-er-EGFP-AEQmut (pLV-erAEQ) was described previously 
Antibody Source Protein MW (kDa) Diluition 
Anti MMP9 (Santa Cruz Biotechnology) Mouse 92 1:200 
Anti VCAM-1 (Santa Cruz Biotechnology) Mouse 110 1:300 
Anti E-selectin (Santa Cruz Biotechnology) Mouse 115 1:800 
Anti Bak (Santa Cruz Biotechnology) Rabbit 30 1:1000 
Anti Bcl-2 (Santa Cruz Biotechnology) Mouse 26 1:300 
Anti-Calreticulin (Sigma Aldrich) Rabbit 55 1:1000 
Anti-Calnexin (Sigma Aldrich) Rabbit 90 1:1000 
Anti-phospho-VEGFR-2 (Sigma Aldrich) Rabbit 230 1:500 
Anti-tubulin (Sigma Aldrich) Mouse 50 1:1000 
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(Lazzari et al., 2011). For generation of pLV-mit-EYFP-AEQmut (pLV-mitAEQ) mitEYFP cassette 
was amplified form pEYFP-mito vector (Clontech) using following primers (5’ to 3’): 
forward CCTCTAGAATGTCCGTCCTGACGCCG;  
reverse CGAAGCTTTGACTTGTACAGCTCGTCCAT;  
disrupting stop codon and generating restriction sites for XbaI (at 5’) and HindIII (at 3’) enzymes. 
HA1-AEQmut cassette was liberated from pCDNA1-er-AEQmut (Montero et al., 1995) using 
HindIII and EcoRI enzymes. mitEYFP and HA1-AEQmut fragments were first subcloned into 
pBSK+ vector (digested with XbaI/EcoRI) in a three-part ligation reaction, after which mitEYFP-
HA1-AEQmut entire cassette was liberated by XbaI/XhoI enzymes and cloned in XbaI/SalI 
digested with pRRLsin.PPTs.hCMV.GFPpre (Follenzi and Naldini, 2002) (pLV) lentiviral vector 
generating pLV-mitEYFP-AEQmut vector referred as to pLV-mitAEQ. 
Lentiviral particles were produced as described previously with minor modifications (Lodola et al., 
2012). Briefly, 2x10e6 HEK293T cells were transfected with pMDLg/pRRE, pMD2.VSVG, pRSV-
Rev and either pLV-erAEQ or pLV-mitAEQ in 100 mm petri dishes using Lipofectamine 2000 
(Life Technologies, Milan, Italy). 48-72 h after transfection culture medium was collected and 
filtered through 0.45 μm PES filter (Millipore Corporation, Bedford, MA, USA). Viral particles 
were precipitated by PEG solution (8% PEG8000, 100 mM NaCl, 0.4 mM TrisHCl, pH 7.2) for 24 
h at 4°C and pelleted by centrifugation (1500 xg, 30 min, 4°C). Pellet was resuspended in PBS at 
1/100 of the initial medium volume, aliquoted and stored at -80°C. Viral particles were titred by 
infecting ECFCs by serial dilutions and examination of EGFP or EYFP fluorescence. The dilutions 
resulting 70–90% of infected cells were used for AEQ experiments. 
For AEQ Ca2+ measurement, RCC-ECFCs and N-ECFCs were spotted onto fibronectin-coated 13 
mm coverslips in a 24 well plate (Costar) at a density 2–3x10e3 cells per spot. 24 hours after plating 
the cells were infected with erAEQ and mitAEQ expressing lentivirus for 48–72 hours. The erAEQ 
was reconstituted in modified Krebs–Ringer buffer (KRB, 135 mM NaCl, 5 mM KCl, 0.4 mM 
KH2PO4, 1 mM MgSO4, 5.5 mM glucose, 20 mM HEPES (pH 7.4) supplemented with 600 μM 
EGTA, 5 μM coelenterazine n and 3 μM ionomycin (all reagents from Sigma) for 1 h at 4°C. After 
reconstitution, the cells were washed 3 times with KRB containing 600 μM EGTA and 2% BSA, 
followed by 3 washes with KRB containing 600 μM EGTA after which the coverslips were 
transferred into perfusion chamber of a custom built aequorinometer (CAIRN research, UK). The 
cells were initially perfused with KRB supplemented with 100 μM EGTA and, after baseline 
recording, the perfusion solution was switched to KRB containing 2 mM Ca2+. Recording continued 
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until the [Ca2+]ER did reach the steady-state level, after that ATP (100 μM) was added to perfusate. 
The mitAEQ was reconstituted in DMEM containing 1% FBS and 5 μM coelenterazine at 37°C for 
1 hour after which the cells were used for experiment. At the end of each experiment the remaining 
AEQ pool was discharged by perfusing distilled water containing 100 mM Ca2+ and 100 μM 
digitonin and the luminescent signals were calibrated off-line into [Ca2+] values using an algorithm 
developed by Brini et al. (Brini et al., 2005).  
 
ELECTRON MICROSCOPY 
ECFCs were fixed with 2% paraformaldehyde and 2.5% glutaraldehyde (Sigma Aldrich) in 0.1 M 
sodium phosphate buffer, pH 7.4. After fixation, cells were postfixed in 2% osmium (OsO4) for 1 
hour at room temperature, dehydrated and embedded in LR White (Sigma Aldrich). Polimerization 
was performed for 24 hours at 60°C. Ultrathin sections were cut with a Reichert (Depew, New 
York) OM-U3 ultramicrotome. The sections were stained with uranyl acetate and lead citrate 
(Sigma Aldrich), examined and photographed at 3000X, 7.000X or 20.000X magnifications on a 
Zeiss (Jena, Germany) EM900 (80kV, objective diaphragm 30µm) electron microscope. 
 
STATISTICS  
All data are expressed as mean ±SE. The significance of the differences of the means was evaluated 
with Student’s t-test. Differences were assessed by the Student t-test for unpaired values.  
All statistical tests were carried out with GraphPad Prism 4.
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RESULTS 
 
THE FREQUENCY OF CIRCULATING RCC-ECFCs IS HIGHER COMPARED TO N-
ECFCs  
The first set of experiments was aimed at ascertaining the phenotypical and functional differences 
between ECFCs isolated from patients with RCC and ECFCs from healthy donors. We focused on 
frequency in PB, growth potential, tubulogenic rate, apoptosis resistance and pro-angiogenic 
response to VEGF. In order to assess whether there was a difference in frequency between N-
ECFCs and RCC-ECFCs, the number of ECFC colonies for 107 MNCs plated in vitro was 
evaluated. As shown in Table 4, RCC-ECFC frequency was significantly higher as compared to N-
ECFCs. 
N-ECFCs (n=34) RCC-ECFCs (n=27) 
0.28* 0.51* 
Table 4. Median value with standard deviation (SD) of ECFCs number for 107 MNC plated 
(p-value=0.027). *=ECFCs frequency for 107 MNCs plated. 
 
 
The frequency median value in patients affected by RCC was 0.51 (with a range 0-7.1) whereas in 
healthy subjects was 0.28 (with a range 0-1.87) colonies for 107 MNCs plated; the p-value was 
0.027 (obtained with a Student’s t-test) which demonstrates the statistical significance of the 
frequency difference. Moreover, the observed significance was maintained also when patients and 
healthy subjects were divided for sex and the number of ECFCs colonies counted and the median 
values compared. Therefore, it could be concluded that the frequency of circulating ECFCs was 
higher in patients with RCC compared with healthy subjects, which is consistent with their 
involvement in tumor vascularization. 
 
RCC-ECFCs AND N-ECFCs SHOW THE SAME IMMUNOPHENOTYPIC PROFILE 
In order to study the immunophenotypic profile of RCC-ECFCs and N-ECFCs and to understand 
whether they express different markers on their surface, early (P1-P2), intermediate (P3-P4), and 
late passages (>P6) of culturing cells were assessed by cytofluorimetric analysis and, in selected 
cases, also by immunocytochemistry reaction on cytocentrifuged cells (Figure 9). The aim was to 
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understand whether in vitro passages could modify the classical ECFC phenotype. Both ECFCs 
from RCC patients and from healthy subjects had the same pattern of expression of surface proteins 
which was similar to that described by Ingram et al. (Ingram et al., 2004); the pattern was 
maintained during cell culture passages. In Table 5 are listed the median values of surface proteins 
expression typical of endothelial (CD31, CD105, CD144 or VE-Caderin, CD146 an vWf) and 
hematopoietic lineage (CD14, CD45). It is evident that N-ECFCs and RCC-ECFCs express all the 
endothelial-specific but not the hematopoietic-specific markers. There was no significant (p<0.05) 
difference in the expression levels of the common endothelial-specific markers between RCC-
ECFCs and N-ECFCs. 
 ECFC P2 (n=3) ECFC P4 (n=3) ECFC P6 (n=2) 
 normal RCC normal RCC normal RCC 
VE-cad 98.70% 99.10% 99.30% 99.20% 98.80% 97.90% 
CD31 99.20% 98.40% 97.10% 98.30% 97.90% 97.20% 
CD105 88.70% 94.90% 92.90% 90.10% 97.10% 98.20% 
CD146 98.90% 99.10% 99.20% 98.20% 97.90% 98.90% 
vWf 98.70% 99.10% 91.80% 95.40% 90.90% 92.10% 
CD45 1.80% 2.20% 0.90% 1.10% 0.70% 0.50% 
CD14 0.80% 1.10% 2.10% 1.90% 0.80% 0.70% 
VEGFR-2 50.3% 49.8% 43% 47.5% 48.5% 51.6% 
Table 5. Percentage of expression of the surface antigens probed for ECFC characterization. 
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Figure 9. Examples of cytofluorimetric and immunocytochemistry analyses conducted for the 
immunophenotypic characterization of ECFCs. 
 
 
THE GROWTH CURVES OF RCC-ECFCs AND N-ECFCs ARE OVERLAPPING 
Next, we assessed whether RCC-ECFCs and N-ECFCs had a different growth potential. Therefore, 
growth curves were evaluated. 2x10 4 ECFCs were plated in 5 collagen treated wells and from the 
next day for 5 days, cells were recovered by trypsinization and counted. The number of RCC-
ECFCs and N-ECFCs detached every 24 hours were compared and shown in Figure 10.  
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Figure 10. Growth curves of RCC-ECFCs (n=10), represented by white squares and N-
ECFCs (n=9), black squares.  
 
 
It was observed that RCC-ECFCs and N-ECFCs growth curves were overlapping, clearly indicating 
that there was not a significant difference in their growth potential in vitro. 
 
IN VITRO TUBULOGENESIS IS NOT DIFFERENT IN RCC-ECFCs AND N-ECFCs 
In order to understand whether N-ECFCs and RCC-ECFCs display differences in their tubulogenic 
capacity in vitro, Matrigel assay was performed as previously described (see Materials and 
methods). The development of a tridimensional capillary-like structure was analysed from 4 to 48 
hours after cell seeding. As shown in Figure 13 (above panel), there was no significant (p<0.05) 
difference in tube length between N-ECFCs and RCC-ECFCs. They did not present any alteration 
either in the tubules formation timing or in the degradation of the same structures during the 
observation period. In Figure 11 (lower panel), two capillary-like structures, representative of 
ECFCs isolated from patients and from healthy subjects, are shown. 
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Figure 11. In vitro tubulogenesis. Above, tube length histogram, measured in mm/mm2 in N-
ECFCs (n=8) and in RCC-ECFCs (n=7). N=N-ECFCs and RCC=RCC-ECFCs. Below, a 
representative example of two Matrigel assays. Capillary-like structures in vitro from a healthy 
subject (N-ECFCs), and from a patient with RCC (RCC-ECFCs) after 12 hours of culture. 
 
 
RCC-ECFCs ARE MORE RESISTANT TO RAPAMYCIN-INDUCED APOPTOSIS AS 
COMPARED TO N-ECFCs 
It has long been known that carcinogenesis is associated to an acquired resistance to pro-apoptotic 
stimulation (Prevarskaya et al. 2014; Prevarskaya et al., 2004). ECFCs do not belong to the 
neoplastic clone, as shown in Piaggio et al. (2009) and discussed in Moccia and Poletto (2014), yet 
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a recent study provided the evidence that endothelial cells may be reprogrammed to develop 
resistance to adriamycin-induced apoptosis in a Ca2+-dependent manner (Dong et al., 2014; Piaggio 
et al., 2009; Francesco Moccia and Poletto, 2014). Therefore, we evaluated the impact of well-
known pro-apoptotic stimuli on RCC- and N-ECFCs. We found that the percentage of apoptotic 
cells induced by rapamycin (5 µg/ml) was significantly (p<0.05) lower in RCC-ECFCs as compared 
to N-ECFCs at both 24 h (Figure 12 (a)) and 48 h (Figure 12 (b)). Notably, RCC-ECFCs were less 
prone to undergo apoptosis even under control conditions at 24 h (Figure 12 (a)).  
 
Figure 12. Resistance to rapamycin-induced apoptosis. Control cells (not treated) and cells 
treated with rapamycin (5 µg/ml) for 24 hours (a) and for 48 hours (b), were analysed by Tunel 
assay. The number of apoptotic cells was registered and reported in histograms. 
 
 
Then, we evaluated the expression of the anti-apoptotic protein Bcl-2 and of the pro-apoptotic 
protein Bak in order to get some hint at the molecular mechanisms of RCC-ECFCs’ apoptosis 
resistance. Surprisingly, both Bak and Bcl-2 were normally expressed in the two cell types (Figure 
13) 
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Figure 13. Expression of Bak (a) and Bcl-2 (b) proteins in ECFCs isolated from healthy 
subjects and from RCC patients. Densitometry in the upper panels and western blots in lower 
panels representative of three separate experiments were shown. Major bands of the expected 
molecular weights for BAK and Bcl-2 were observed. Each bar in the upper panel represents the 
mean±SD of the densitometric analysis of three different experiments. Proteins bands derive from 
the same experiment, thus tubulin bands are common to the two proteins studied. 
 
 Overall, these data demonstrate that RCC-ECFCs were more resistant to apoptosis as compared to 
their healthy counterparts. Nevertheless, this pro-survival feature was not due to an anti-apoptotic 
oncoprotein dependent mechanism. 
 
VEGF INDUCES THE NUCLEAR TRANSLOCATION OF NF-kB (p65) IN N-ECFCs IN A 
Ca2+-DEPENDENT MANNER 
Finally, we evaluated whether VEGF-induced, NF-kB-mediated protein expression changes 
between N-ECFCs and RCC-ECFCs. Previously, our laboratory has demonstrated that VEGF 
causes IkB phosphorylation (Dragoni et al., 2011), but did not assess whether this actually induces 
the nuclear translocation of NF-kB. We thus exploited immunocytochemistry to determine the 
localization of RelA/p65, a major subunit of NF-kB.  
 61 
Figure 14. Nuclear NF-kB translocation after VEGF stimulation. Immunocytochemistry assay 
of p65 in N-ECFCs untreated (CTRL) and treated with VEGF (10 ng/ml) for 15 minutes, 1 and 2 
hours. The arrows indicate the presence of fluorescent signal in nucleus of cells treated with VEGF. 
The first column shows the fluorescent p65 signal, the second column the nuclei coloured by DAPI 
and the third one the merge. 
 
Under resting condition, p65 protein-dependent fluorescence was predominantly located in the 
cytoplasm (Figure 14, CTRL). However, VEGF (10 ng/ml) caused the rapid translocation of p65 
into the nucleus, which is fully concurrent with the findings on IkB phosphorylation reported by 
Dragoni et al. (2011). The fluorescent signal associated to p65 protein was evident in the nucleus 
already at 15 m after VEGF stimulation and persisted as long as 2 hours. In order to assess whether 
VEGF-induced Ca2+ oscillations drive the nuclear translocation of p65, we pre-treated the cells with 
BAPTA (30 µM), which is a membrane-permeable buffer of intracellular Ca2+, and BTP-2 (20 µM), 
which is a selective inhibitor of SOCE and dramatically curtails the Ca2+ train (Dragoni et al., 
2011). 
 62 
Figure 15. Nuclear NF-kB translocation after VEGF and inhibitors stimulation. 
Immunocytochemistry assay of p65 in N-ECFCs treated with VEGF+BAPTA (30µM) and 
VEGF+BTP-2 (20µM) The first column shows the fluorescent p65 signal, the second column the 
nuclei coloured by DAPI and the third one the merge. 
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As shown in Figure 15, both BAPTA and BTP-2 fully prevented the nuclear translocation of NF-
kB, thereby confirming that NF-kB translocates into the nucleus in N-ECFCs challenged with 
VEGF (Dragoni et al., 2011). 
 
VEGF INDUCES GENE AND PROTEIN EXPRESSION IN N-ECFCs 
The next step was to assess whether VEGF-induced, NF-kB-mediated protein synthesis actually 
occurs in N-ECFCs. We evaluated the expression of a number of VEGF-dependent genes involved 
in key cellular processes, such as proliferation, apoptosis, adhesion, and survival, by qRT-PCR. The 
genes analysed were: B-cell lymphoma 2 gene (BCL2), involved in apoptosis; VCAM1, ICAM and 
E-SELE involved in cell adhesion; MMP9 involved in the breakdown of extracellular matrix; cyclin 
D1 (CCND1) and C-MYC involved in cell cycle regulation. N-ECFCs were treated with VEGF (10 
ng/ml), and cDNA subsequently amplified with primers specific for the selected genes (see 
Materials and methods). As shown in Figure 16, VEGF induced a significant increase in E-SELE 
and VCAM1 expression after 2 and 4 hours of incubation; however, after 6 hours, the expression 
dramatically decreased at unstimulated levels. The genes BCL2, ICAM1 and CCND1 showed the 
maximum value of fold change after 2 hours of VEGF stimulation. After this timing, gene 
expression levels returned to basal values or lower. Moreover, VEGF seemed not to promote 
MMP9 gene expression although a trend toward an increase was observed with a maximum at 4 
hours of VEGF stimulation. Finally, C-MYC expression was not influenced in VEGF-stimulated N-
ECFCs. Three genes (E-SELE, VCAM1 and MMP9), which showed the highest increase in their 
transcript levels, were then selected to confirm their expression at protein level through western blot 
analysis. We showed that VEGF (10 ng/ml) significantly (p<0.05) enhanced the expression of E-
SELE, VCAM1 and MMP9 in N-ECFCs at 4 hours after the beginning of the stimulation (Figure 
17). 
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Figure 16. Expression of selected genes transcripts in N-ECFCs after VEGF cell treatment. 
Gene expression experiments using relative quantification (relative to controls which assume values 
of 1) in N-ECFCs stimulated with VEGF (10 ng/ml) for 2, 4 and 6 hours (x axis). 0 hours (0 h) 
corresponds to untreated controls. On y axis are represented the average values and standard 
deviation of fold change values. In these sets of experiments ECFCs from 13 healthy subjects have 
been analysed. 
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Figure 17. Expression of E-SELE, VCAM1 and MMP9 proteins in N-ECFCs after VEGF 
treatment. E-SELE (a), VCAM1 (b) and MMP9 (c) protein expression was analyzed in N-ECFCs 
under control conditions (not treated) and after treatment with VEGF (10 ng/ml). Densitometry in 
the upper panels and western blots in lower panels representative of four separate experiments were 
shown. Major bands of the expected molecular weights for E-SELE, VCAM1 and MMP9 were 
observed. Each bar in the upper panel represents the mean±SD of the densitometric analysis of four 
different experiments. The asterisk indicates p<0.05 (Student’s t-test). Protein bands derive from 
the same experiment, thus tubulin bands are common to the three proteins studied. 
 
 
In agreement with our previous data, VEGF-induced protein expression was dramatically reduced 
by BTP-2 (20 µM), BAPTA (30 µM), and thymoquine (25 µM), a selective NF-kB blocker (Figure 
18). 
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Figure 18. Expression of E-SELE (a), VCAM1 (b) and MMP9 (c) proteins in ECFCs isolated 
from healthy subjects. Protein expression was analyzed under control conditions (not treated), 
after treatment with VEGF (10 ng/ml), and after stimulation with specific inhibitors: BTP-2 (20 
µM), BAPTA (30 µM) and Thymoquinone (25 µM). Densitometry (upper panels) and western blots 
(lower panels) representative of four separate experiments were shown; data have been normalized 
to percentage of expression inhibition. Major bands of the expected molecular weights for E-SELE, 
VCAM1 and MMP9 were observed. Each bar in the upper panel represents the mean±SD of the 
densitometric analysis of four different experiments. The asterisk indicates p<0.05 (Student’s t-
test). Proteins bands derive from the same experiment, thus tubulin bands are common to the three 
proteins studied. 
 
 
Collectively, these findings demonstrate that NF-kB mediates the VEGF-induced and Ca2+-
dependent expression of VCAM1, MMP9 and E-SELE in N-ECFCs 
 
VEGFR-2 IS ACTIVATED BUT VEGF-INDUCED PROTEIN EXPRESSION IS NOT 
ENHANCED IN RCC-ECFCs.  
Once confirmed that VEGF induces NF-kB-dependent protein expression in N-ECFCs, we 
evaluated VEGF effect on RCC-derived cells. We first ascertained whether VEGF induces protein 
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expression in RCC-ECFCs as previously demonstrated for N-ECFCs. Therefore, we treated the 
cells with VEGF (10 ng/ml) and analysed by western blot VCAM1, E-SELE and MMP9 protein 
expression. Our results clearly show that, unlike for N-ECFCs, VEGF did not induce any protein 
expression in ECFCs from patients with RCC (Figure 19) despite the fact that VEGFR-2 is 
normally expressed in these cells. 
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Figure 19. Expression of E-SELE, VCAM1 and MMP9 proteins in RCC-ECFCs after VEGF 
treatment. E-SELE (a), VCAM1 (b) and MMP9 (c) protein expression was analyzed in RCC-
ECFCs under control conditions (not treated) and after treatment with VEGF (10 ng/ml). 
Densitometry (upper panels) and western blots (lower panels) representative of four separate 
experiments were shown. Major bands of the expected molecular weights for E-SELE, VCAM1 and 
MMP9 were observed. Each bar in the upper panel represents the mean±SD of the densitometric 
analysis of four different experiments. Proteins bands derive from the same experiment, thus tubulin 
bands are common to the three proteins studied. 
 
 
The present results and those presented by Lodola et al. (2012) demonstrate that RCC-ECFCs fail to 
respond to VEGF. Therefore, we wondered whether VEGFR-2 is functional in these cells. The 
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auto-phosphorylation and consequent activation of VEGFR-2 (VEGFR-2P) were studied by 
western blot analysis in N- and RCC-ECFCs challenged with VEGF (10 ng/ml). As shown in 
Figure 20, there was no significant (p<0.05) difference in the extent of VEGFR-2 
autophosphorylation between N-ECFCs and RCC-ECFCs. These data suggest that the lack of a 
Ca2+-dependent pro-angiogenic response to VEGF is due to a defect in the Ca2+-signalling 
machinery downstream of VEGFR-2.  
 
Figure 20. Expression of VEGFR2-P in ECFCs isolated from N-ECFCs and from RCC-
ECFCs. Densitometry (a) and western blots (b) representative of three separate experiments were 
shown. A major band of the expected molecular weights for VEGFR2-P proteins was observed. 
Each bar in the upper panel represents the mean±SD of the densitometric analysis of three different 
experiments. 
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STEADY STATE ER Ca2+ LEVELS AND MITOCHONDRIAL Ca2+ UPTAKE ARE 
REDUCED IN RCC-ECFCs 
Our phenotypical and functional characterization has revealed that N-ECFCs and RCC-ECFCs 
differ in two main aspects: RCC-ECFCs are more resistant to apoptosis and are insensitive to VEGF 
despite the fact that VEGFR-2 is normally expressed and activated. These features hint at the drop 
in ER Ca2+ levels as the major responsible for these very important functional differences between 
the two cell types. Accordingly, a decrease in ER and, consequently, mitochondrial Ca2+ levels is a 
common means by which neoplastic cells become resistant to pro-apoptotic stimuli (Skryma et al., 
2000; Vanden Abeele et al., 2002; Vanoverberghe et al., 2004). Moreover, the reduction in 
intraluminal Ca2+ could prevent RCC-ECFCs from generating a detectable increase in [Ca2+]i in 
spite of InsP3 production. The data obtained by our laboratory suggested, but not experimentally 
confirmed that the ER Ca2+ load in RCC-ECFCs is lower as compared to N-ECFC (Lodola et al., 
2012). Therefore, we sought to directly evaluate the [Ca2+]ER by expressing ER-targeted Aequorine 
(AEQ) in both types of cells.  
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Figure 21. Sub-cellular measurement of Ca2+ levels in N-ECFCs and RCC-ECFCs. (a) Steady-
state [Ca2+]ER in N-ECFCs is significantly higher as compared to RCC-ECFCs. In order to 
confirm ER-targeting of the aequorin probe, Ca2+ release from ER after ATP (100 µM) treatment 
was evaluated. (b) Mean±SE of [Ca2+]ER in N-ECFCs and RCC-ECFCs. The asterisk indicates 
p<0.05. (c) ATP-induced, InsP3-dependent increase in [Ca2+] is significantly higher in N-ECFCs as 
compared to RCC-ECFCs. (d) Mean±SE of [Ca2+]mit in N-ECFCs and RCC-ECFCs. The asterisk 
indicates p<0.05.ATP was administrated at 100 µM. Agonists and extracellular solutions containing 
different concentrations of Ca2+ were administered at the time indicated by the horizontal bars.  
 
 
We found that [Ca2+]ER was significantly (p<0.05) lower in RCC-ECFCs as compared to their 
normal counterparts (Figure 21 (a) and (b)), while the InsP3-producing autacoid ATP (100 µM), 
fully depleted intraluminal Ca2+ in both cell types (Figure 21(a)). Likewise, the amount of ER Ca2+ 
mobilized by ATP was significantly (p<0.05) higher in N-ECFCs as related to tumor ECFCs 
(Figure 21(a) and (b)). Next, we exploited mitAEQ to evaluate the ATP-induced, InsP3-dependent 
elevation in mitochondrial Ca2+ concentration ([Ca2+]mit) in both N- and RCC-ECFCs (Lodola et al., 
2012). InsP3-evoked Ca2+ signals were constitutively transferred to the mitochondrial matrix by the 
ER-mitochondrial shuttle and a reduction in the amount of Ca2+ redirected by InsP3R towards the 
mitochondria is an established mechanism for apoptosis resistance in cancer cells (Prevarskaya et 
al., 2014; Prevarskaya et al., 2013; Prevarskaya et al., 2004). In agreement with the reduction in 
their [Ca2+]ER, RCC-ECFCs displayed a lower InsP3-dependent increase in [Ca2+]mit as compared to 
N-ECFCs (Figure 21 (c) and 21 (d)). Taken together, these data confirmed that the [Ca2+]ER was 
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remarkably lower in RCC-ECFCs and such dysregulation reflects in a decrease in the amplitude of 
mitochondrial InsP3-induced Ca2+ elevations.  
 
THE ENDOTHELIAL Ca2+ TRANSPORTING SYSTEMS AND ER Ca2+ BINDING 
PROTEINS ARE NOT ABERRANTLY EXPRESSED IN RCC-ECFCs 
Our previous results strongly suggested that the chronic depletion of ER Ca2+ content in RCC-
ECFCs was determined by their slower SERCA activity (Lodola et al., 2012). In order to get deeper 
insights into the mechanisms responsible for the drop in [Ca2+]ER in RCC-ECFCs, we evaluated the 
mRNA expression of the most widespread endothelial transporter and pump isoforms, i.e. 
SERCA2B, SERCA3, PMCA1A, PMCA1B, PMCA4B, NCX1.3 and NCX1.7 . We found that both 
N- and RCC-ECFCs only expressed SERCA2B, PMCA1B and PMCA4B (Figure 22(a)). 
Furthermore, the comparison of mRNA levels obtained by qRT-PCR did not assess any quantitative 
difference in the transcript levels of these Ca2+-transporting systems between N- and RCC-ECFCs 
(Figure 22(b)).  
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Figure 22. Gene expression analysis of the most widespread Ca2+-clearing mechanisms in N-
ECFCs and RCC-ECFCs. (a) Both N-ECFCs (left panel, white bars) and RCC-ECFCs (right 
panel, black bars) only express SERCA2B, PMCA1B and PMCA4B transcripts. On x axis are 
reported the genes studied and on y axis the percentage of their expression relative to an 
housekeeping gene (GAPDH). Each bar represents the mean±SE of three different experiments 
each from different RNA extracts. (b) Relative fold change in gene expression of the three genes 
expressed in (a). On y axis are represented the average values and standard errors of fold change 
values. In these sets of experiments, ECFCs from 3 healthy subjects and 3 patients have been 
analysed. (S2B=SERCA2B; S3=SERCA3; P1A=PMCA1a; P1B=PMCA1b; P4A=PMCA4a; 
P4B=PMCA4b; N1.3=NCX1.3; N1.7=NCX1.7) 
 
 
The next step was to analyse the expression of the two most important ER Ca2+-binding proteins, 
namely calreticulin and calnexin, in N- and RCC-ECFCs. Nevertheless, both proteins were 
normally expressed in N- and RCC-ECFCs (Figure 23(a) and (b)). Consequently, the decrease in 
[Ca2+]ER did not involve either the remodelling of the ER Ca2+-handling proteins (i.e. SERCA), as 
well as those of the plasma membrane (i.e. PMCA and SERCA), or the down-regulation of the 
luminal Ca2+ binding/storage chaperones, calreticulin and calnexin. 
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Figure 23. Expression of Calreticulin and Calnexin proteins in N- and RCC-ECFCs. 
Densitometry (upper panels) and western blots (lower panels) representative of three separate 
experiments were shown. Major bands of the expected molecular weights for Calreticulin and 
Calnexin proteins were observed. Each bar in the upper panel represents the mean±SD of the 
densitometric analysis of three different experiments. Proteins bands derive from the same 
experiment, thus tubulin bands are common to the two proteins studied. 
 
 
ULTRASTRUCTURAL REMODELLING OF RCC-ECFCs 
The reduction in Ca2+-storage capacity could also involve a long-term rearrangement of ER 
structure (Sammels et al., 2010), which might collapse and loose its ability to sequester sufficient 
amount of Ca2+. A thorough ultrastructural analysis of both N- and RCC-ECFCs was, therefore, 
carried out at electron microscopy level. This investigation disclosed major morphological 
differences between the two cell types. Cisternae of rough endoplasmic reticulum (rER) are evident 
in both N- and RCC-ECFCs (Figure 24; Table 6): however, they are closely arranged in the former, 
while are more widely spaced and occupy a wider area in the latter. Multivesicular bodies can 
frequently be found between these rER cisternae in tumor-derived ECFCs (Figure 24; Table 6). 
Likewise, smooth ER (sER) can be found as constituted by vesicles and tubules, although its 
presence is rather scarce in N-ECFCs (Figure 24; Table 6). Conversely, sER is present in the form 
of large vesicles occupying a large part of the cytoplasm in RCC-ECFCs. This peculiar shape is 
most likely due to the fact that he tubules normally present are seemingly enlarged into vesicles. 
Finally, we evaluated mitochondrial numbers and morphology in both cell types. In control cells, 
mitochondria are mainly present as short, roundish organelles, showing wide-spaced cristae, while 
they are more abundant and very frequently elongated and branched in tumor-derived cells, 
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possibly due, as in other cases, to a fusion or incomplete separation (Figure 24; Table 6). Overall, 
the ultrastructural remodeling observed in RCC-ECFCs, i.e. ER expansion and increase in number 
and size of mitochondria, are strikingly different from our expectations, but do confirm that normal 
and tumor-derived ECFCs profoundly differ from each other. 
 
 
Figure 24. Ultrastructural analysis of ECFCs morphology. Representative images of two RCC-
ECFCs and two N-ECFCs samples analyzed. The bars in a-f correspond to 500 nm. (a)-(c) N-
ECFCs: Two round mitochondria (arrowheads) display widely separated cristae (a); r-ER cisternae, 
closely arranged, are evident in the cytoplasm (b); Smooth endoplasmic reticulum is scanty, and 
present in the forma of small vesicles and tubules (c). (d)-(f) RCC-ECFCs: mitochondria 
arrowheads are larger, branched and striated by numerous cristae (d); r-ER occupies a wider area, 
and the cisternae appear to be widely spaced. Note the presence of multivesicular bodies (e); the s-
ER can be seen as composed by numerous large vesicles, present on a wider area than in control 
cells (f) 
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Cell Type Structure 
Total 
analysed ER 
area (µm2) 
Number of 
mitochondria 
per cell 
Total analysed 
mitochondria 
area (µm2) 
N-ECFCs s-ER 0.937±0.245 4.2±0.4 0.722±0.112 
RCC-ECFCs s-ER 2.564±0.369* 8.4±2.0* 0.993±0.312 
N-ECFCs r-ER 0.277±0.241   
RCC-ECFCs r-ER 1.241±0.253*   
Table 6. Measurements of ultrastructural analysis of ECFCs morphology. Averages±SE; 
values shown were obtained from 17 images of N-ECFCs and from 19 images of RCC-ECFCs 
obtained from two distinct donors and examined at XXXX magnification. The asterisk indicates 
p<0.05. 
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DISCUSSION 
Endothelial progenitor cells can be isolated from MNCs of BM, UCB, PB and from large arteries 
walls (Yoder, 2012). They normally reside in BM niches from where they can be mobilized and 
circulate in PB to replace damaged/senescent endothelial cells or to restore blood perfusion in 
ischemic tissues (Massa et al., 2009); circulating EPCs can be recruited to their final destination 
through an interplay between chemokine and adhesion molecules with mechanisms not yet defined 
clearly (De Falco et al., 2004). Lyden, in 2001, provided the first evidence of EPCs involvement in 
tumor vasculature, followed by Gao et al who showed their involvement in the metastatic switch. 
They demonstrated that EPCs are able to home to micrometastatic foci, thereby promoting the 
transition to macrometastasis. Despite the strong evidence of EPCs involvement in tumor 
angiogenesis, many authors denied their role in the angiogenic switch, as they could not provide the 
evidence of their incorporation into tumor neovessel (De Palma et al., 2003; Göthert et al., 2004). 
These highly contrasting data could derive from the lack of a final and definite phenotypical 
characterization of EPCs, but can also be explained by the fact that EPCs could interact in 
angiogenesis at different stages according to the tumor type (Gao et al., 2009).  
Considering the debate on EPCs and their possible involvement in cancer angiogenesis, our group, 
who has always been focussing on the involvement of EPCs in myeloprolipherative disorders, 
decided to analyse ECFCs from cancer patients. In collaboration with San Matteo Clinical 
Oncology Department, we decided to investigate if ECFCs isolated from healthy subjects and from 
patients affected by RCC could show significant phenotypical or functional differences, although 
RCC-ECFCs do not belong to malignant clone. Furthermore, we tried to characterize N- and RCC-
ECFCs behaviour after stimulation with cytokines such as VEGF, the most important ECFCs 
clonogenic stimulus. 
San Matteo Clinical Oncology Department holds one of the most important national centres for 
metastatic RCC treatment and could provide us with fresh blood samples of patients with RCC, 
after proper informed consent has been obtained. RCC is a good model for tumor angiogenesis 
studies as its strong dependence on angiogenesis has already been shown. The main mutation 
known to be associated with RCC cancerogenesis is the VHL gene mutation. VHL inactivation 
leads to the reduction of HIF-1α ubiquitination with the consequent transcription of pro-angiogenic 
receptor proteins, such as c-Met, and growth factors, such as TGF-a, CXCL-12, PDGF-b and VEGF 
(Lonser et al., 2003). Among of all these, VEGF plays a crucial role in endothelium homeostasis as 
well as in tumor neoangiogenesis. RCC therapy for advanced forms (local ones, if early treated, can 
be totally cured in most cases) has been almost fruitless up to the first years of this century, but it is 
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not surprising that the first compounds which could influence the natural history of the disease have 
been principally directed, being either mAbs or TKI, against VEGF or its receptor. Despite a 
dramatic increase of PFS in patients treated with anti-angiogenic drugs, the OS is not improved 
much, and long lasting responses are just rare cases. Another striking problem is represented by 
patients who intrinsically, primary, do not respond to this class of molecules. A better 
understanding of RCC pathogenesis could lead to the evidence of alternative targetable pathways 
which could also be directed to the microenvironment rather than just to the cancerous cell itself. 
Tumor microenvironment has gathered attention as a possible regulator of carcinogenesis since the 
beginning of the last decade, as many scientific evidences suggested that the tumor cell does not 
only interact with the surrounding endothelial cells, but can also be influenced by other surrounding 
normal stromal and immune cells. Tumor microenvironment has thus been studied as a possible 
primary actor in cancerogenesis, rather than a secondary player just influenced by tumor 
development. Many cell populations have been suggested playing roles during tumor growth, 
including TAM, CAF, myofibroblasts, adypocites and, of course, endothelial cells. We cannot rule 
out that the trigger mechanism promoting the transformation of a normal epithelium into a 
malignant phenotype does not primarily lie in the epithelium itself, but rather derives from the 
surrounding, disturbed, environment (Albini and Sporn, 2007). The microenvironment is thus a 
critical subject to investigate in the aim of better understanding cancer growth and progression; the 
aforementioned evidences hint at EPCs as key contributors of tumor, and in particular of RCC, 
microenvironment. For these reasons, it is clear the growing interest about EPCs both from a 
biological viewpoint, as contributors to neoangiogenesis, and as potential therapeutic target to 
impair tumor growth. 
The phenotypical and eventually functional identification of EPCs is fundamental: phenotypical 
characterization alone can already suggest some possible interactions between cell 
microenvironment and tumor growth, as for the case of M2 type TAM favouring cancer progression 
as opposed to M1 type TAM, protecting from it (Albini and Sporn, 2007). As far as we know, EPCs 
contribute to tumor neoangiogenesis, despite being not cancerous cells: therefore we tried to 
compare the behaviour of ECFCs isolated from healthy donors with ECFCs isolated from RCC 
patients based on the earlier evidence that their pro-angiogenic Ca2+ toolkit is dysregulated (Lodola 
et al., 2012). To date, most studies addressed the chromosomic, genetic and functional differences 
arising between normal endothelial cells and TECs (Aird, 2012; Hida et al., 2013; Dudley, 2012). 
Unfortunately, TECs are only barely compared with normal matched endothelial cells from the 
same tissue. Moreover, when this is possible, control endothelial cells are obtained from peri-
tumoral samples that could be influenced by tumor microenvironment and/or carry some of the 
genetic aberrations as the neoplasm (Aird, 2012; Dudley, 2012). Conversely, we used as control the 
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same cell population investigated in tumor patients, i.e. circulating ECFCs, but derived from 
healthy donors. We initially focussed on the number of circulating EPCs in healthy subjects 
compared to RCC patients. From our observations, the first difference between N-ECFCs and RCC-
ECFCs was their frequency in PB, calculated as number of colonies for 107 MNCs plated. RCC-
ECFCs were significantly more frequent than N-ECFCs (p-value = 0.027). Besides differences in 
PB frequency of ECFCs, RCC-ECFCs and N-ECFCs show the same immunophenotypic profile, the 
one described by Ingram et al. in 2004, the same potential growth, studied by growth curves, and 
the same ability to develop a tridimensional capillary-like structure in Matrigel assay. This data 
could support anyway the hypothesis that phenotypically normal ECFCs could cooperate in tumor 
growth; their enhanced mobilization can be explained by the possibility that the tumor 
microenvironment secretes growth factors or cytokines specific for ECFCs recruitment from BM. A 
higher frequency can thus be explained either by a higher mobilization, or by an increase in BM 
production of these progenitors. This evidence is anyway difficult to obtain as we lack of both RCC 
patient and healthy donors BM samples. The data obtained are in line with other clinical studies in 
which EPCs were evaluated under their possible role as cancer biomarker. Yang et al. and Bhatt et 
al. compared EPC frequency between RCC patients and healthy donors showing higher statistically 
significant frequencies of EPCs in RCC patients; these data must be considered and compared 
carefully as the debate about the phenotypical EPCs characterization is still largely open and we 
find many different representatives of EPCs in PB, which might lead to slightly different 
conclusions (Yang et al., 2012; Bhatt et al., 2011). 
Tumor-derived endothelial cells are less sensitive to pro-apoptotic stimulation as compared to 
healthy cells. For instance, both RCC- and breast cancer derived TECs are more resistant than 
normal endothelial cells to serum-starvation and chemotherapeutics, such as temozolomide, 
doxorubicin and vincristine (Bussolati et al., 2011). The constitutive activation of the 
phosphoinositide-3-kinase-Akt (PI3K/Akt) pathway has been linked to the higher TEC resistance to 
apoptosis (Bussolati et al., 2003; Bussolati et al., 2011). Likewise, if stimulated with rapamycin, 
molecule that is known to induce apoptosis through the inhibition of the mTOR pathway, RCC-
ECFCs are more resistant to apoptosis than N-ECFCs; this was evident both at 24 h and 48 h, in a 
statistically significant fashion on a TUNEL assay. Stating this evidence, we decided to investigate 
the expression of some proteins whose role in apoptosis is well established and we evaluated the 
expression of the anti-apoptotic protein Bcl-2 and of its pro-apoptotic counterpart Bak. Western blot 
analysis on cell lysates showed that there was no significant difference in the protein expression for 
both Bcl-2 and Bak between N-ECFCs and RCC-ECFCs, suggesting that the pro-survival 
phenotype of RCC-ECFCs was not due to an oncoprotein dependent mechanism. 
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Even if RCC-ECFCs do not belong to a malignant clone, and despite them showing the same 
phenotype and ability to form tubular capillary structure on Matrigel as their healthy counterpart, 
they differ in frequency and in resistance to apoptotic stimuli. These evidences suggest a potential 
role of EPCs in tumor development and support the hypothesis that they could also resist better to 
pro-apoptotic damages such as the ones induced by some anti-angiogenic therapies used in RCC 
treatment as well as by some classical chemotherapeutic drugs (to which RCC has always shown 
intrinsic resistance). 
RCC-ECFCs do only differ from N-ECFCs in terms of apoptosis resistance. VEGF stimulates N-
ECFCs by evoking intracellular Ca2+ oscillations that promote the Ca2+-dependent ubiquitination of 
IkB. This process should in turn promote the nuclear translocation of the pro-angiogenic 
transcription factor NF-kB (Dragoni et al., 2011). However, the nuclear translocation of NF-kB in 
N-ECFCs was not assessed in this study. Moreover, preliminary data from our group revealed that 
VEGF fails to trigger intracellular Ca2+ oscillations in RCC-ECFCs (Lodola et al., 2012). Therefore, 
we then ascertained whether VEGF promotes NF-kB-dependent protein expression in RCC-ECFCs. 
We found that the nuclear translocation of NF-kB initiated at already at 15 minutes from the 
beginning of the stimulation and persisted as long as two hours afterwards. Consistent with the data 
reported in (Dragoni et al., 2011), the nuclear translocation of NF-kB was inhibited by preventing 
VEGF-induced Ca2+ oscillations with BAPTA and BTP-2. These results were further mimicked by 
thymoquinone, a selective NF-kB inhibitor. NF-kB is thus the link between Ca2+ signalling and 
gene and protein expression after VEGF stimulation. To further confirm this statement, we focussed 
on VEGF-elicited gene expression and found that VEGF induces the transcription of E-SELE, 
VCAM1, MMP9, BCL2, ICAM, CCND1, but not of C-MYC. In agreement with mRNA data, 
VEGF enhanced the expression of E-SELE, VCAM1 and MMP9 proteins. Moreover, VEGF-
induced expression of E-SELE, VCAM1, and MMP9 proteins was significantly reduced by 
BAPTA, BTP-2 and thymoquinone. These experiments demonstrate that VEGF-induced Ca2+ 
oscillations promote protein expression in N-ECFCs through the nuclear translocation of NF-kB. 
Although Lodola et al. have already shown that RCC-ECFCs do not produce any Ca2+ response to 
VEGF, we evaluated VEGF-induced protein expression in RCC-ECFCs. We further confirmed that 
RCC-ECFCs are insensitive to VEGF stimulation as western blot analysis revealed that E-SELE, 
VCAM1 and MMP9 protein expression was not enhanced after 4 hours of stimulation. As VEGFR-
2 expression in expressed on RCC-ECFCs surface (Lodola et al., 2012), we studied VEGFR-2 
activation through western blot experiments: VEGFR-2 is present and phosphorylated (VEGFR2-P) 
in both healthy and RCC-derived ECFCs. We thus demonstrated, that although VEGF does not 
 82 
induce protein expression, VEGFR-2 is expressed and normally activated by this growth factor in 
RCC-ECFCs. These data led us to speculate that VEGF fails to stimulate pro-angiogenic Ca2+ 
oscillations in RCC-ECFCs as a consequence of the inhibition/down-regulation of a signalling 
pathway triggered by VEGFR-2.  
The comparison of the immunophenotypical and functional properties displayed by N- and RCC-
ECFCs, therefore, highlighted two main differences: tumor-derived ECFCs are more resistant to 
apoptosis and are insensitive to VEGF. Another data only suggested by Lodola et al. (2012), which 
in part could explain the differences reported in our study between RCC-ECFCs and N-ECFCs, was 
the Ca2+ concentration in ER and mitochondria. RCC-ECFCs present a dramatic rearrangement of 
their Ca2+ toolkit that seemingly leads to the reduction of ER-dependent Ca2+ release due to the 
concomitant drop in [Ca2+]ER and InsP3R down-regulation (Lodola et al., 2012). Such re-
arrangement of the Ca2+ machinery might affect RCC-ECFC behavior in two ways. InsP3Rs redirect 
Ca2+ from ER to mitochondrial matrix through the ER-mitochondrial shuttle. Mitochondria 
represent a central integration point for the signals regulating cell destiny (Ivanova et al., 2014; 
Murgia et al., 2009; Sammels et al., 2010). Cellular Ca2+ overload, which may be triggered by 
various initial stimuli, promotes mitochondrial Ca2+ uptake. Excessive Ca2+ accumulation within the 
mitochondria is one of the primary causes for mitochondrial permeability transition, which is at 
least in part mediated by the opening of permeability transition pore (PTP), a multiprotein complex 
located at the contact sites between the inner and the outer mitochondrial membranes. PTP opening 
permits the release of mitochondrial apoptogenic factors into the cytoplasm where they in turn 
activate death-executing caspase cascade. Mitochondrial permeability in general, and PTP complex 
in particular, is regulated by the members of Bcl-2 family of proteins, of which those preventing 
apoptogenic factors release, Bcl-2, Bcl-xL, and Mcl-1 protect against apoptosis, whereas those 
promoting it, Bak and Bax, act as apoptosis enhancers (Bonora and Pinton, 2014; Giorgi et al., 
2012). As a consequence, a reduction in [Ca2+]ER is a biological trick exploited by cancer cells to 
become less sensitive to apoptosis (Prevarskaya et al., 2014). Pioneering work ideed unveiled that 
LNCaP (Lymph Node Carcinoma of the Prostate16) prostate cancer epithelial cells undergo a 
significant Bcl-2 down-regulation, yet they become resistant to apoptosis by virtue of the drop in 
steady state [Ca2+]ER (Prevarskaya et al., 2004; Vanden Abeele et al., 2002; Vanoverberghe et al., 
2004). Similarly, the chronic reduction in intraluminal Ca2+ levels results in apoptosis resistance in 
small cell lung cancer (H1339) and adenocarcinoma lung cancer (HCC) cell lines (Arbabian et al., 
2013; Bergner et al., 2009). Thus, if confirmed, a drop in ER Ca2+ levels could explain RCC-ECFC 
resistance to rapamycin-induced apoptosis. Moreover, it could explain the lack of a pro-angiogenic 
Ca2+ response to VEGF: despite the fact that InsP3 is normally synthesized upon VEGFR-2 
phosphorylation, the fall in [Ca2+]ER will prevent the onset of the following Ca2+ oscillations and the 
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activation of their down-stream pro-angiogenic machinery (i.e. the nuclear translocation of NF-
KB). 
We therefore used ER-AEQ and mit-AEQ to confirm that ER Ca2+ levels are significantly lower in 
RCC-ECFCs and that this dysregulation is translated in a decrease in the amplitude of 
mitochondrial Ca2+ uptake. Aequorin-based measurements are indeed an established procedure to 
measure Ca2+ levels within sub-cellular organelles, such as ER, mitochondria, lysosomes and 
nucleoplasm. The reasons that could explain why [Ca2+] is significantly lower in ER and 
mitochondria of RCC-ECFCs in comparison with N-ECFCs are still unclear, but several factors 
may determine the chronic underfilling of ER Ca2+ content in RCC-ECFCs. First, a reduction in 
SERCA expression would dampen Ca2+ sequestration and result in a lower [Ca2+]ER. For instance, 
SERCA2b is down-regulated during the transition of prostate cancer to the aggressive androgen-
independent phenotype (Vanden Abeele et al., 2002; Vanoverberghe et al., 2004). Similarly, H1339 
and HCC cell lines present lower levels of SERCA2 protein (Bergner et al., 2009), whereas 
SERCA3 is selectively decreased or lost during colon and breast carcinogenesis (Papp et al., 2012). 
Second, the up-regulation of the Ca2+-transporting systems on the plasma membrane would limit 
SERCA-dependent Ca2+ uptake by the ER. In this view, PMCA1 and PMCA2 transcripts are up-
regulated in several breast cancer cell lines (Lee et al., 2006), while PMCA4 is over-expressed in 
H7-29 colon cancer cells (Aung et al., 2009). Nevertheless, our thorough transcriptomic analysis 
revealed that: 1) both N- and RCC-ECFCs only express SERCA2B, PMCA1B and PMCA4B; and 
2) the expression of these Ca2+ pumps is normal in tumor-derived cells. It is herein worth of noting 
that we could not detect the most widespread endothelial NCX isoforms, i.e. NCX1.3 and 1.7 
(Moccia et al.,2012). This feature is consistent with our preliminary results (Dragoni, Tanzi and 
Moccia, unpublished data), according to which removal of extracellular Na2+ does not lead to any 
increase in [Ca2+]i in ECFCs, as otherwise predicted by the recruitment of the reverse-mode of NCX 
(Berra-Romani et al., 2010; Moccia et al., 2002). Third, a decrease in the expression of ER-Ca2+ 
binding proteins would severely compromise ER capability of storing Ca2+, as shown in prostate 
and lung cancers. Accordingly, calreticulin is down-regulated and causes a decrease in [Ca2+]ER in 
both androgen-independent prostate cancer cells (Vanden Abeele et al., 2002; Vanoverberghe et al., 
2004) and in H1339 and HCC cell lines (Bergner et al., 2009). Conversely, there was no difference 
in calreticulin and calnexin expression between N- and RCC-ECFCs. Therefore, an alternative 
mechanism must be invoked to understand the reduction in intraluminal ER Ca2+ levels in tumor-
derived ECFCs. Our previous study demonstrated that the decay to the baseline of the Ca2+ transient 
induced by ATP in 0Ca2+ in RCC-ECFCs is significantly slower as compared to healthy cells 
(Lodola et al., 2012). Under such conditions, Ca2+ clearance from the cytosol is mainly 
accomplished by SERCA activity (Berra-Romani et al., 2010; Moccia et al., 2002). Conversely, the 
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recovery of CPA-induced increase in [Ca2+]i to resting Ca2+ is not impaired in RCC-ECFCs and is 
carried out by PMCA and NCX as SERCA is inhibited by this treatment (Lodola et al., 2012). This 
result led us to conclude that SERCA activity is slower in RCC-ECFCs, a feature which might 
contribute to explain the fall in [Ca2+]ER reported in the present investigation. SERCA is sensitive to 
the oxidative stress that features tumor microenvironment and attenuates its Ca2+-pumping rate 
(Vangheluwe et al., 2005). For instance, both reactive oxygen and nitrogen species (ROS and RNS, 
respectively) target and inactivate SERCA2, thereby causing the derangement of ER Ca2+-
dependent signalling that features heart failure and skeletal muscle fatigue (Vangheluwe et al., 
2005). However, the oxidative stress imposed by tumor microenvironment to its cellular 
constituents may not be the only reason for the inhibition of SERCA activity in RCC-ECFCs. A 
large gene-profiling study recently conducted by our group has demonstrated that RCC-ECFCs 
over-express the tetratricopeptide repeat-containing adapter protein TMTC1 (Tancredi, Della Porta, 
Porta, Rosti, and Moccia, not shown), which binds to and inhibits SERCA2B activity, thus causing 
a reduction in ER Ca2+ levels (Sunryd et al., 2014). Future work will have to assess whether 
TMTC1 dysregulation affects [Ca2+]ER also in RCC-ECFCs.  
The alteration in Ca2+-storage capacity might also depend on the long-term remodeling of ER 
structure in RCC-ECFCs (Sammels et al., 2010). For instance, the up-regulation of the ER Ca2+ 
pool and Ca2+-dependent hyper-inflammatory response has been associated to ER expansion in 
cystic fibrosis human airway epithelium (Ribeiro, 2006; Ribeiro and O’Neal, 2012). The same 
chain of events has been suggested to occur in the inflammatory bowel disease and during plasma-
cell differentiation (Sammels et al., 2010). Moreover, ER remodeling may determine the extent of 
InsP3-releasable Ca2+ during oocyte maturation (Lim et al., 2003; Santella et al., 2004). It has long 
been known that ER develops cortical clusters in maturing oocytes of hamster, mouse and Xenopus, 
thereby leading to an increase in the Ca2+ response to InsP3 (Kline, 2000). Surprisingly, our EM 
analysis revealed that the decrease in [Ca2+]ER is associated to a remarkable ER expansion, rather 
than collapse, in RCC-ECFCs. Thus, these cells are endowed with a larger ER, but their slower 
SERCA activity results in a decrease, rather than an increase, in their overall Ca2+ levels. This is the 
first time that such a rearrangement in ER structure has been described in an endothelial cell type 
under neoplastic conditions. The decline in steady-state [Ca2+]ER may confer a survival advantage 
by conferring higher resistance to apoptosis, but poses a serious problem for the correct functioning 
of the ER. Synthesis, folding, and orderly transport of proteins are tightly regulated by the ER-
resident and Ca2+-dependent chaperones calreticulin and calnexin. A chronic Ca2+ depletion of the 
ER causes an imbalance between the cellular demand for protein synthesis and the capacity to 
satisfy such request. This results in the accumulation of misfolded or unfolded proteins, a condition 
that has been referred to as ER stress (Mekahli et al., 2011; Sammels et al., 2010). As discussed in 
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Prevarkaya’s work, in 2013, tumor cells must cope with the chronic underfilling of the ER and 
develop adaptive mechanisms to face the reduction in [Ca2+]ER (Prevarskaya et al., 2013). The 
unfolded protein response (UPR) is the survival strategy that cancer cells activate to reestablish the 
protein-folding ability of ER (Walter and Ron, 2011; Wang and Kaufman, 2014). One of the 
hallmarks of UPR is actually represented by ER expansion, which is mediated by the transcription 
factor X-box binding protein-1 (XBP-1) and alleviates ER stress independently on any increase in 
ER chaperone levels (Walter and Ron, 2011; Schuck et al., 2009). Therefore, we speculate that ER 
remodeling is an adaptive mechanism by which RCC-ECFCs withstand the chronic drop in [Ca2+]ER 
that enable them to evade apoptosis. In this view, it is worth of noting that RCC-ECFCs display 
many more mitochondria as compared to control cells. It turns out that a lower amount of ER-
derived Ca2+ could be constitutively transferred in an InsP3-dependent manner to a larger number of 
mitochondria to fuel cell bioenergetics without reaching the threshold of induction of apoptotis 
cascade causing resistance to apoptotic stimuli.  
Overall, these results clearly demonstrate that RCC-ECFCs display a lower [Ca2+]ER as compared to 
control cells which reflects into a lower InsP3-dependent increase in [Ca2+]mit and involves a slower 
SERCA activity. The chronic underfilling of the ER Ca2+ pool might underpin both the two key 
functional differences observed between normal and RCC-derived ECFCs: i.e. their higher 
resistance to apoptosis and lower sensitivity to VEGF. These findings could be crucial for 
redirecting anti-angiogenic therapies towards a more effective path. Anti-angiogenic therapies in 
RCC are likely to fail after a few months after the beginning of the treatment (or to fail immediately 
in the so called ‘primary refractory’ patients). This is almost inevitable except for a few, selected 
and anecdotic cases. In the last few years, research has focused on the molecular mechanisms that 
eventually lead to resistance to targeted therapies, and many alternative signalling pathways seem to 
be activated after the selective pressure induced by anti-angiogenic molecules, e.g. c-Met-HGF/SF 
or bFGF (Porta et al., 2013). Resistance mechanisms have anyway been mostly explored in tumor 
cells, while very few attempts have been trying to evaluate the role of the microenvironment. From 
our observations, we now know that tumor-derived ECFCs are more resistant to apoptosis and to 
VEGF stimulation. This latter feature is not linked to a blockade of VEGFR itself, but to a 
downstream dysregulation of this pathway. The drop in [Ca2+]ER represents the most likely 
explanation to understand why ECFCs are less sensitive to apoptosis and to VEGF. These rather 
unexpected observations lead to the intriguing hypothesis that EPCs play a key role in mounting 
RCC patients resistance to anti-VEGF therapies. 
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CONCLUSION 
In conclusion, our work provides a wide phenotypical and functional comparison between ECFCs 
isolated from healthy individuals and from individuals affected by renal cell carcinoma. We found 
that ECFCs are more frequent in peripheral blood of patients with RCC as expected by their 
predicted role in neovascularization. RCC-ECFCs truly belong to the endothelial lineage and are 
able to form capillary-like structures in vitro. Unlike TECs, there is no difference either in the 
proliferation or tubulogenic rates between normal and tumor-derived ECFCs; however, the latter are 
more resistant to pro-apoptotic stimulation. Additionally, RCC-ECFCs are not sensitive to VEGF, 
although VEGFR-2 is normally expressed and activated by VEGF, which in turn induces NF-KB-
dependent gene and protein expression in N-ECFCs. We further demonstrated that RCC-ECFCs 
present a lower ER and mitochondrial Ca2+ content as compared to normal cells, albeit the ER 
undergoes a remarkable expansion. The chronic drop in ER Ca2+ levels is seemingly due to a slower 
SERCA activity and could underpin both the higher resistance to apoptosis and the lower sensitivity 
to VEGF. The remodeling of the Ca2+ toolkit might thus be exploited not only by tumor cells, but 
also by tumor-associated ECFCs to promote cancer development. Although RCC-ECFCs do not 
belong to the neoplastic clone (Piaggio et al., 2009), our data clearly show that they differ from the 
same population in normal individuals. Growing evidence has demonstrated that bone marrow-
derived EPCs are reprogrammed by tumor-secreted soluble mediators or exosomes to favor tumor 
growth, vascularization, and metastatization (Barcellos-Hoff et al., 2013; Moccia and Poletto, 2014; 
Plummer et al., 2013). These data corroborate the notion that carcinogenesis alters ECFCs, a truly 
endothelial EPC subtype, by impacting on their intracellular Ca2+ toolkit (Dragoni, Turin, et al. 
2014; Lodola et al. 2012). The role of EPCs in human tumors is not yet fully elucidated, but we 
would like to speculate that EPCs engraft within neoangiogenesis sites and constitute one of the 
factors inducing the resistance to anti-angiogenic treatments. Accordingly, the resistance to 
apoptosis related to the chronic reduction in [Ca2+]ER is predicted to confer a survival advantage to 
RCC-ECFC within the hostile microenvironment of the growing tumor, thereby favoring their 
engraftment in nascent vessels and accelerating RCC expansion and spreading (Moccia and Poletto, 
2014). Moreover, the remodelling of the Ca2+ machinery in RCC-ECFCs prevents the stimulating 
effect of VEGF. This feature could have a tremendous impact on the therapeutic efficacy of anti-
angiogenic treatments. Endothelial cells isolated from the primary tumor are quite sensitive to 
VEGF, which is required for them to proliferate, survive to pro-apoptotic insults and form capillary-
like structures in vitro (Bussolati et al., 2003). Thus, anti-VEGF drugs will cause significant tumor 
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shrinkage at the beginning of the therapy by blocking local angiogenesis; this, however, will rapidly 
lead to hypoxia-induced secretion of further growth factors and cytokines, e.g. VEGF, bFGF, EGF, 
SDF-1α and angiopoietins, and recruitment of BMDCs to the collapsing tumor. Herein, ECFCs, 
and perhaps all the other EPC subgroups, will not be affected by the therapeutic inhibition of 
VEGFR-2, which does not deliver pro-angiogenic signals to these cells. Consequently, ECFCs will 
be incorporated within tumor vasculature and fuel the formation of new blood vessels, thereby 
favouring tumor rebound. This adaptive mechanism would enable the tumor to circumvent the anti-
angiogenic strategy by reducing its dependence on VEGF. This scenario is fully compatible with 
the modes of resistance to anti-angiogenic therapies suggested by Bergers and Hanahan (Bergers 
and Benjamin, 2003), by Carmeliet and coworkers (Loges et al., 2010), and by Ellis and Hicklin 
(Ellis and Hicklin, 2008). These results further imply that signalling pathways other than VEGF 
activate RCC-ECFCs; such hypothesis is corroborated by the well known up-regulation of multiple 
pro-angiogenic factors that may readily substitute for each other in cancer patients. These include 
the already mentioned bFGF, EGF, angiopoietins, as well as placental growth factor (PGF), 
osteopontin, granulocyte colony-stimulating factor (G-CSF), and ephrins (Bergers and Hanahan, 
2008; Loges et al., 2010). Consistently, in a large fraction of kidney cancer patients who developed 
resistance to sunitinib, the metastatic progression was preceded by an increase in the circulating 
levels of bFGF, hepatocyte growth factor (HGF) and interleukin-6 (IL-6) (Porta et al., 2013). Future 
experiments will have of course to challenge these hypotheses. It will be mandatory to assess 
whether: 1) ECFC do engraft within RCC neovessels and 2) restoring the [Ca2+]ER in RCC-ECFCs 
rescues their sensitivity to pro-apoptotic stimulation and VEGF. 
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E così anche questo percorso si conclude, non senza prove, non senza difficoltà, ma d’altro canto, 
se così non fosse stato, quale sarebbe la soddisfazione? 
Non posso che essere grata al Prof. Guerra per avermi dato questa meravigliosa possibilità di 
crescita professionale e personale. 
Un particolare grazie al Prof. Moccia e al Dott. Rosti per avermi insegnato ad amare la Scienza, la 
ricerca, ad essere curiosa e a capire che non sono mai troppe le ore spese a fare quello che si ama, 
qualunque cosa essa sia. Grazie a voi, per avermi spronato quando pensavo di non farcela, quando 
avete creduto in me quando io non ci credevo, quando mi avete detto, guardandomi negli occhi: 
“andrà tutto bene”, anche se forse nessuno di noi aveva la certezza di come sarebbe finita. 
A tutta la mia famiglia che mi ha tenuto la mano e ha combattuto al mio fianco, col sorriso e la 
dolcezza, accanto a me nei momenti in cui la speranza veniva meno, a ricordarmi che con l’amore 
e il sostegno di uno sguardo si può provare ad affrontare ogni battaglia. 
Alla subacquea, come sport, come scoperta e come persone che mi hanno insegnato a conoscerla, 
perché come nella ricerca, anche sott’acqua ci vuole testa e tanta tanta passione.  
Ed infine grazie alla Prof.ssa Cinelli, che sono sicura sarebbe stata felice ed emozionata nel 
sentirmi presentare i dati del lavoro che abbiamo fatto insieme. Mi avrebbe sorriso e sostenuto con 
la sua infinita dolcezza e gentilezza. Avrà sempre un posto speciale nel mio ricordo. 
 
